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PART A: PROTOCOL 
1. Introduction 
The industrial revolution, which spread across the world, transformed societies from being 
primarily agrarian to relying on technology for mass production. Essential to this revolution 
was the use of power machines and factories to maximise the number of goods and services 
provided to communities1. Despite its many advantages, including; the creation of jobs and 
the mass production of goods and services to sustain societies, this revolution is also 
associated with the production of high levels of pollutants2 
1.1 Problem Statement 
The World Health Organisation (WHO) has estimated that in 2016, 4.2 million deaths were 
attributed to ambient air pollution. Furthermore, the majority of these deaths occurred in 
lower and middle-income countries with cardiorespiratory diseases being the main 
mechanism through which these deaths occurred3. 
1.2 Justification 
Studies investigating the relationship between air pollution and health outcomes date back to 
the 20th century 4,5. Subsequently, many studies have been conducted to further explore this 
association. However, most of these studies have been conducted in America, Asia and Europe 
where air pollution levels and population characteristics differ from those found in Africa and 
specifically in informal settlements around South Africa6-13. Furthermore, there is a paucity of 
studies on the continent investigating this relationship, as avalaible studies do not have robust 
exposure measurements, make use objective outcomes and/or do not control for appropriate 
confounders (some of which vary across different study population). Moreover, majority of 
studies from the African continent have focused mainly on children. The proposed study aims 
to investigate the relationship between ambient air pollution and cardiorespiratory outcomes 
amongst adults residing in four informal settlements in the Western Province while controlling 
for relevant confounding variable and will thus contribute to the growing body of literature on 
this topic on the continent.  
1.3 Research Question 
What is the association between ambient air pollution and cardiorespiratory outcomes in 
South African adults in 2016? 
1.4 Aim 
The aim of the study is to investigate the relationship between ambient air pollution exposure 
and self-reported cardiorespiratory outcomes amongst adults residing in four informal 
settlements of the Western Cape 
 
 
 
 
 
 
1.5 Objectives 
The objectives are: 
• To describe the demographics and host characteristics of the study population 
• To assess exposure to seld-reported indoor and estimated ambient air pollutants of the 
study participants 
• To assess self-reported cardiorespiratory outcomes of the study participants 
• To explore potential confounding variables that may be associated with 
cardiorespiratory outcomes of interest 
• To determine the association between exposure to ambient air pollution and self-
reported cardio respiratory outcomes 
 2. Literature Review 
The World Health Organisation Air Quality Guidelines have identified four criteria ambient 
air pollutants that have adverse effects on health. These pollutants include particulate matter 
(PM), sulphur dioxide (SO2), nitrogen dioxide (NO2) and ozone (O3)
14. Carbon monoxide 
(CO) has also been shown to have adverse health effects15. 
2.1 Particulate matter 
Particulate matter affects more people than any other pollutant and mainly contains: mineral 
dust, black carbon, ammonia, sodium chloride, sulphate nitrates and water 16, 17, 18. Particles 
of 10 microns or less have the greatest adverse health effect as they are small enough to lodge 
deep into the lungs18. The main sources of PM include vehicle emissions, agriculture, power 
generation and other industrial sources14, 19. PM has also been shown to increase diastolic 
blood pressure and put the body in an inflammatory and procoagulant state20,21. Furthermore, 
PM induces oxidative stress, causes airway irritation by impairing mucociliary and 
macrophage activity and has been shown to be carcinogenic22.  
2.2 Sulphur Dioxide 
Sulphur dioxide is a toxic gas with a pungent, irritating and rotten smell. It is mainly derived 
from fossil fuel combustion at power plants and other industrial facilities23 ,24. Smaller 
sources of SO2 emissions include industrial processes such as extracting metal ore, the 
burning of high sulphur containing fuels by vehicles, large ships and non-road equipment. 
Ecologically, SO2 emissions are a precursor to acid rain which results in deforestation
14. SO2 
has been shown to reduce cardiac vagal tone (parasympathetic control of the heart) and thus 
results in increased susceptibility to arrhythmias25. It is also an irritant to the eyes, nose and 
respiratory tract and causes bronchoconstriction22. 
2.3 Nitrogen Dioxide 
Nitrogen dioxide is a reddish-brown toxic gas with a sharp, biting odour. It is mainly derived 
from combustion processes used in the generation of power, heating, ships and vehicles14, 26. 
NO2 plays a primary role in the formation of ozone and therefore contributes to the 
cardiovascular effects of ozone27.It also impairs gaseous exchange and increases bronchial 
reactivity and susceptibility to respiratory infections22. 
2.4 Ozone 
Ozone is the most important photochemical oxidant in the troposphere and is formed by 
photochemical reactions in the presence of precursor pollutants such Nitrogen Oxides and 
Volatile Organic Compounds. O3 has been shown to impair gaseous exchange in the alveoli 
and therefore induces increased myocardial stress14.It also impairs gaseous exchange and 
induces respiratory tract mucosal inflammation22. 
2.5 Carbon Monoxide 
Carbon monoxide is a colourless, odorless and tasteless gas that is slightly less dense than air.    
It is produced from partial oxidation of carbon containing compounds and forms when there 
is insufficient oxygen to produce carbon dioxide. Its main sources are gas stoves, wood 
stoves, fireplaces and vehicles28. It is toxic to haemoglobic animals (including humans) at 
concentrations above 35ppm and causes its harmful health effects by reducing oxygen 
delivery to the body’s organs (including the heart and brain) and tissues29. Acute exposure to 
carbon monoxide has been associated with headache, dizziness on exertion, nausea and 
mental confusion. Chronic exposure to carbon monoxide has been associated with flu like 
symptoms, unconsciousness and death15.  
2.6 Outdoor air pollution and cardiovascular disease in Africa 
Ghana and South Africa were included in the World Health Organisation Study on Global 
Ageing and Adult Health. Analysis of data from the study found that there was a 1.13(95%CI 
1.05 to 1.22) increased odds of stroke with each 10µg/m3 increase in PM2.5 
30. In addition, in 
South Africa, an interquartile increase in PM10 was also found to be associated with a 
4.1%(95%CI 0.4 to 8.1) increased risk of mortality attributed to cerebrovascular causes and a 
10µg/m3 increase in NO2 was found to be associated with a 3.4%(95%CI 0.3 to 6.6) and 
8.0(95%CI 2.9% to 13,4%) increased risk of mortality attributed to cardiovascular and 
cerebrovascular diseases respectively31. Furthermore, in Algeria, it was found that decreasing 
PM10 annual mean by 5µg/m
3 would avoid 3 cardiac hospitalisations32 
2.7 Outdoor air pollution and respiratory disease in Africa 
In South Africa, a 12µg/m3 increase in PM10 and 10µg/m
3 increase in NO2 were found to be 
associated with a 5.5 %( 95 CI, 1.4 to 9.6) and 6 %( 95%CI 1 to 112.) increase in mortality 
attributable to respiratory diseases and a cross sectional study conducted in Nigeria found a 
negative correlation between increasing levels of PM10 and lung function
31, 33. Furthermore, 
in Algeria, decreasing the annual PM10 by 5µg/m
3 reduced five hospital admissions 
attributable to respiratory diseases and a study conducted in Namibia also found a significant 
association between particulate matter and episodes of coughing and phlegm 32,34. 
2.8 Conclusion 
Despite the majority of ambient air pollution related deaths occurring in lower- and middle-
income countries, there is a paucity of epidemiological studies investigating ambient air 
pollution’s effect on health in Africa. Furthermore, in addition to the above-mentioned 
methodological limitations, all but one of the epidemiological studies conducted in Africa 
investigating the association between air pollution and cardiorespiratory morbidity only made 
use of particulate matter as an air pollutant. Further research in this field thus needs to be 
conducted on the continent to not only contribute to the body of knowledge in this field but 
also to generate information which will assist health authorities to take appropriate measures 
to promote health on the continent. 
3. Methodology 
3.1 Study Population and Study Design 
This study involved the analysis of a sub-set of data that was collected as part of a larger 
study conducted in 2016. The larger study was a cohort study investigating the effect of 
ambient air pollution on asthma among 600 primary school pupils in the Western Cape35. The 
current study is a cross-sectional study investigating the effect of ambient air pollution on 
cardiorespiratory outcomes among the guardians of primary school students in the Western 
Cape. The study areas included informal settlements in three areas prioritised in a needs 
analysis conducted by the department of Environmental Affairs and Development Planning 
(DEADP) in 2013. Furthermore, one control area (an area with a low air pollution score 
ranking) with community members of similar socio-economic status as the three identified 
areas was identified (Mashiphumelel in Noordhoek). These areas were selected to maximise 
contrasts in exposure levels to the different ambient air pollutants. The exposed areas 
included an urban industrialised area (Marconi Beam in Milnerton), a peri-urban area with a 
large informal sector (Khayelitsha) and a rural area (Oudtshoorn). 
3.2 Selection of study areas  
The selection of study areas in the larger study was informed by a scoring process based on 
the World Health Organisation’s (WHO) Driving Force, Pressure, State, Exposure, effects, 
Action (DPSEA) framework. This framework aims to integrate health and environment in 
developing countries dealing with various hazards (e.g. water and food insecurity, 
HIV/AIDS, malaria etc.) which increases their vulnerability and reduces their ability to cope 
in situations of environmental pollution exposure.  
The scoring process assigned a Total Prioritisation Index (PI) for all the census areas (i.e. 
statistical data from the census 2011) in the different Districts within the Western Cape. The 
PI was calculated from an air pollution score, the population density (number of people per 
square kilometre), total population, and susceptibility and coping score. Hence, an area with 
poor air quality (but with few people) had a lower score for prioritization compared to an area 
with similar air quality but with more population density. Details of the prioritization process 
and methodology have been described elsewhere 36. A weighted average was applied to 
represent the interaction of the various factors to obtain a Total Prioritisation Index as follows: 
Total Prioritisation Index = (0.5*Air Pollution Score) + (0.1*population density) + 
(0.1*population) + (0.3*Vulnerability Score-susc&cop)  
 
The conclusion drawn from the findings of the Total Prioritization Index across the different 
municipalities in the Western Cape clearly indicated a significant high intensity of exposure, 
susceptibility of communities to air pollution, as well as vulnerability, in the City of Cape Town 
compared to other municipals. The Total Prioritization Index was normalized from 1 to 100, 
with 100 being the most vulnerable site. However, the selection of an urban industrialised area 
(Marconi Beam in Milnerton), a peri-urban area (Khayelitsha) and a rural area (Oudtshoorn) 
was to maximize contrasts between the various areas for various ambient air pollutants and 
patterns of pollutants.  
 
 
 
3.3 Sampling and sample size 
In the larger study, a list of all the schools in the study area was obtained from the Department 
of Education. One or two schools were subsequently located near the City’s air monitors. One 
hundred and fifty Grade 4 students in each study area were targeted. Grade 4 students were 
targeted because they were old enough to participate in the study and would not leave primary 
school to enter high school during the study period. 
After meeting each school’s principal, obtaining permission from the school board and 
obtaining the grade 4 class lists and addresses, the houses of school children were visited by 
trained field staff to obtain the caregivers (parent or guardian) consent. 
Inclusion criteria for the larger study included: all grade 4 students attending selected schools, 
all grade 4 students with asthma not selected randomly. Exclusion criteria included: children 
who had recent operation (within the last 12 months), children who felt like vomiting or had 
any pain, children with epilepsy, children being treated for Tuberculosis and children with flu, 
sinusitis or lung infection in the last 3 weeks. The guardians of these children selected in the 
main study were selected for this cross-sectional analytical study.  
Using chi square statitistic for comparing two independent samples with the null hypothesis: 
proportion 1 = proportion 2 and the alternative hypothesis proportion 1 != proportion 2 the 
following outcomes had the following power 
For the NO2 model 
• Doctor diagnosis of asthma: using sample size = 572, allocation ratio = 3.2, propotion 
1 = 0.0142, proportion 2 = 0.0299; power = 6.45 
• Asthma symptom score: using sample size = 572, allocation ratio = 1.4, propotion 1 = 
0.0898, proportion 2 = 0.1276; power = 25.09 
• Self -reported chest pain: using sample size = 572, allocation ratio = 3.5, propotion 1 = 
0.0126, proportion 2 = 0.0441; power = 21.76 
• Self -reported hypertension: using sample size = 572, allocation ratio = 1.8, propotion 
1 = 0.0488, proportion 2 = 0.0787; power = 21.64 
• Self -reported high cholesterol: using sample size = 572, allocation ratio = 2.3, 
propotion 1 = 0.0142, proportion 2 = 0.0331; power = 6.45 
For the PM2.5 model 
• Doctor diagnosis of asthma: using sample size = 572, allocation ratio = 2.1, propotion 
1 = 0.0142, proportion 2 = 0.0299; power = 10.11 
• Asthma symptom score: using sample size = 572, allocation ratio = 1.2, propotion 1 = 
0.0976, proportion 2 = 0.1197; power = 10.43 
• Self -reported chest pain: using sample size = 572, allocation ratio = 2.3, propotion 1 = 
0.0173, proportion 2 = 0.0394; power = 16.02 
• Self -reported hypertension: using sample size = 572, allocation ratio = 1.3, propotion 
1 = 0.0567, proportion 2 = 0.0709; power = 7.4 
• Self -reported high cholesterol: using sample size = 572, allocation ratio = 2, propotion 
1 = 0.0157, proportion 2 = 0.0315; power = 10.45 
 
 
 
 
 
3.4 Instruments 
3.4.1 Questionnaire 
Trained interviewers administered the questionnaires to participants in their spoken language 
(English, Xhosa or Afrikaans). The principle investigator and study co-ordinator provided 
training on administration of the questionnaire to the fieldworkers.  The questionnaire was 
back-translated to ensure the consistency and reliability of the questionnaires. The use of 
mobile technology was implemented in the administration and capture of questionnaires. 
The questionnaire used for this study included items on: 
• Demographic factors 
• Residential History 
• Respiratory Health 
• Cardiovascular Disease 
• Blood Pressure and other chronic illnesses such as high cholesterol 
• Occupational History 
• Exposure to Indoor Pollutants  
• Exposure to Outdoor Pollutants 
• Physical Activity 
• Psychosocial Stress 
• Tobacco Use 
Appendix 1 depicts questions asked in each section 
The European Community Respiratory Health Survey37 and National Health and Nutrition 
Examination Survey questionnaire38 was incorporated into the study’s questionnaire 
administered to each grade 4 participant’s guardian. From these questionnaires the following 
cardiorespiratory outcomes could be obtained: 
• Doctor diagnosis of Asthma 
• Wheezing 
• Breathlessness 
• Woken up by feeling of tight chest in the last 12 months 
• Shortness of breath in the last 12 months 
• Shortness of breath after exercise in the last 12 months 
• Woken up by attack of shortness of breath in the last 12 months 
• Phlegm from chest in winter 
• Woken up by coughing in last 12 months 
• Seld-reported asthma 
• Medication for asthma control 
• Seld-reported chest pain 
• Seld-reported hypertension 
• Seld-reported high cholesterol 
An asthma symptom score was created from the responses to 8 asthma questions: wheezing in 
last 12 months, shortness of breath in last 12 months, woken up by feeling of tight chest in the 
last 12 months, attack of shortness of breath at rest in the last 12 months, attack of shortness of 
breath after exercise in the last 12 months, woken up by attack of breath in the last 12 months, 
self-reported asthma and medication for asthma control. A score of 1 was allocated for each 
positive response. 
 
3.5 Exposure Characterisation 
The annual average concentration of PM2.5 and NO2 was estimated at each participant’s 
address by land-use regression (LUR) models developed specifically for this study39. In brief, 
the air pollution monitoring campaigns were performed during 2015-2016 in each study area. 
Weekly measurements of PM2.5 and NO2 were performed in both winter and summer at 140 
sites (40 sites each in three study areas, except 20 sites in Masiphumulele) within a period of 
1 year. These measurements were temporally adjusted using routinely monitored air quality 
measurements to obtain the seasonal (winter/summer) and annual averages. Predictors of 
exposure, obtained or collected on-site, such as household density, nearby traffic (e.g. major 
roads, bus stops, and train stations), waste burning sites, and land-use derived from 
geographic information system (GIS) were used to evaluate the spatial variation in the annual 
average concentrations. To maximize the adjusted explained variance, regression models 
were developed, using a supervised stepwise approach, and the models were validated using 
leave-one-out-cross-validation (LOOCV). The LUR model was used to estimate annual 
average concentration of PM2.5 and NO2 for each participant’s address. 
3.6 Statistical Analysis 
A pilot study was conducted before the start of the main study to pilot the measuring 
instruments and logistics of the study.  
Table 1 summarises the variables used in the data analysis. 
Table 1: List of exposure and outcome variables 
Variable Name Original Measurement 
scale 
Units/Categorisation 
Age Numerical  Years 
Gender Categorical Female/Male 
Education Categorical Never attended school or 
only pre- school or primary 
school/Completed 
Highschool 
 
Employed Categorical Yes/No 
Home language Caegorical Isixhosa/Afrikaans, English 
or other 
Current Residence Categorical Have lived elsewhere/Have 
never lived elsewhere before 
Type of place of birth Categorical Farm/Village in rural 
area/Small town/Suburb of a 
city/Inner City 
House Type Categorical Brick house/Shack/ Other 
(Room in back yard, shack in 
backyard, Hut, Caravan, 
Wood house 
Air conditioning in home Categorical Yes/No 
Fuel used to heat house or 
cooking 
Categorical Fuel other than electricity 
(wood, coal, gas, paraffin, 
cattle manure, solar or 
charcoal)/Electricity 
 
Door or window open 
while cooking 
Categorical Most of the time/Some of the 
time/Rarely/Do not have a 
door or window that opens to 
the outside 
Sleep with open windows Categorical All of the 
time/Sometimes/Never 
Water damage to building 
or its content 
Categorical Yes/No 
Water damage in last 12 
months 
Categorical Yes/No 
Damp spots inside house 
in last 12 months 
Categorical Yes/No 
Efforts done to reduce 
allergies 
Categorical Yes/No 
Have Pets Categorical Yes/No 
Frequency of walking a 
mile or more without 
stopping in the last month 
Numerical 1-100 
Exercise done in past 
month 
Categorical Yes/No 
Number of times exercise 
per month 
Numerical 1-100 
Receiving Emotional 
Support 
Categoical Yes/No 
Received emotional 
support within last 12 
months 
Categorical Yes/No 
Receiving financial 
support 
Categorical Yes/No 
Smoke cigarettes Categorical Yes/No 
Daily number of cigarettes 
smoked 
Numerical 1-100 
Number of years smoking Numerical 1-100 
Pack years Numerical 1-100 
Doctor diagnosed asthma Categorical Yes/No 
Wheezing in the last 12 
months 
Categorical Yes/No 
Shortness of breath in last 
12 months 
Categorical Yes/No 
Woken up by feeling of 
tight chest in the last 12 
months 
Categorical Yes/No 
Attack of shortness of 
breath at rest in the last 12 
months 
Categorical Yes/No 
Attack of shortness of 
breath after exercise in the 
last 12 months 
Categorical Yes/No 
Woken up by attack of 
shortness of breath in the 
last 12 months 
Categorical Yes/No 
Bring up phlegm from 
chest at any time of day in 
the winter 
Categorical Yes/No 
Woken up by heavy 
coughing at any time in 
the last 12 months 
Categorical Yes/No 
Self-reported asthma Categorical Yes/No 
Medication for asthma 
control 
Categorical Yes/No 
Affected by animals, dust 
or pollen from trees or 
flowers 
Categorical Yes/No 
Self-reported experience 
Chest Pain 
Categorical Yes/No 
Self-reported hypertension Categorical Yes/No 
Self-reported cholesterol Categorical Yes/No 
NO2 (summer) Numerical µg/m3 
NO2 (winter) Numerical µg/m3 
NO2 (annual) Numerical µg/m3 
PM2.5 (summer) Numerical µg/m3 
PM2.5 (winter) Numerical µg/m3 
PM2.5 (annual) Numerical µg/m3 
 
Data was captured, cleaned and analysed in Stata: Release 11 (StataCorp. 2009. Statistical 
Software. College Station, TX: StataCorp LP). Descriptive statistics was used to examine the 
characteristics of the study population, cardiorespiratory outcomes and various confounders. 
Bivariate regression was used to measure associations between various confounders and cardio 
respiratory outcomes. Confounders identified apriori and those with significant associations 
(p<0.15) were included in multi logistic regression models (Appendix D). Forward selection 
was then used to select the most parsimonious model. Collinearity of variables was assessed 
by calculating the variable inflation factor and variables with an inflation factor greater than 10 
were removed from each model. Only variables decribed in literature to be associated with the 
outcomes variables and those with a biological plausible relation to te outcome variables were 
included in the models to .Area was not adjusted fo in the models as it did not uncover any 
significant associations and did not improve the models in the sensitivity analysis. 
3.7 Study Limitations 
The study was restricted to the Western Province which could have different air pollution 
levels to other provinces. The findings of this study should therefore not be extrapolated to 
other provinces. Furthermore, the outcome measure was collected with questionnaires and so 
misclassification of outcomes could have occurred. Lastly, the cross-sectional nature of the 
study means that inferences about causality cannot be made. 
 3.8 Ethical Considerations  
The larger study was done in accordance with the Declaration of Helsinki of the 25th world 
Medical Assembly. The main study was approved by the University of Cape Town’s Research 
Ethics Committee (ethics number: 234/2009). The protocol for the sub study was approved by 
the University of Cape Town’s Research Ethics Committee (ethics number: 639/2018).  
The houses of school children from the main study was visited by trained field staff to explain 
the study, answer the questions that the parents/guardians had, obtain the caregivers (parent or 
guardians) consent and complete the European Community Respiratory Health Survey and 
National Health and Nutrition Examination Survey questionnaire. Informed consent from the 
caregivers was obtained. The consent form explained: the proposed research, risks and 
discomforts of testing, the expected benefits of the research, how confidentiality would be 
preserved and how confidentiality would be documented, there would be no costs for testing 
and list the details of people that could be contacted regarding the research. It also served as an 
assurance that participants could decline to participate in the study with no penalty. 
All information and data are kept in records at the University of Cape Town. All files are locked 
in cabinets. To protect confidentiality, the consent forms and contact information sheets are 
stored apart from the confidential study information.  They are kept in a separate locked file 
cabinet. Participants were referred to their local clinic or family practitioner for further 
management when problems were detected. 
The findings of the research will be disseminated through journal publications as scientific 
literature. A copy of the report will also be made available at the University of Cape Town 
Medical School Library. Furthermore, information sheets on the risk of air pollution and how 
to manage these risks were distributed to school staff and caregivers of participating students. 
4. Logistics 
 
4.1 Work plan for 2018 
Activity/Plan January February March April May June July August September October November December 
Protocol 
Development 
            
Structured 
Literature 
Review 
            
Data 
Analysis 
            
Manuscript 
Development 
            
Final thesis 
prep and 
submission 
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PART B : STRUCTURED LITERATURE REVIEW 
1. Background 
The World Health Organisation (WHO) has estimated that in 2016 4.2 million deaths were 
attributed to ambient air pollution. Furthermore, the majority of these deaths occurred in 
lower and middle-income countries with cardiorespiratory diseases being the main 
mechanism through which these deaths occurred1.  
Although the pollutant mix is complex, the WHO Air Quality Guidelines (AQG) identified 
four important criteria ambient air pollutants that have adverse health effects. These 
pollutants include: particulate matter (PM), sulphur dioxide (SO2), nitrogen dioxide (NO2) 
and ozone(O3)
2. Additionally, carbon monoxide (CO) has also been shown to have adverse 
health effects3. Table 1 summarises the main properties of the air pollutants2-22. 
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Table 1: Summary air pollutants 
Air pollutant Source  General information Detrimental effects Recommended Levels 
Particulate Matter (PM) Vehicle emissions, 
agriculture, power 
generation 
-Most dangerous air 
pollutant 
-Components include: 
mineral dust, black 
carbon, ammonia, 
sodium chloride, sulphate 
nitrates and water 
-Commonly classified 
according to size: course 
(PM2.5-10 µm), fine (PM ≤ 
2.5 µm or PM2.5) and 
ultrafine (PM < 0.1 µm 
or PM0.1) 
-Increases blood pressure 
by decreasing Nitrogen 
Dioxide (vasodilator) or 
increasing endothelin-1 
(vasoconstrictor) 
-Induces oxidative stress 
and consequently, 
pulmonary and systemic 
inflammation 
-Puts the body in a pro 
coagulant state 
-Impairs mucociliary and 
macrophage activity and 
causes airway irritation 
-Prolonged exposure 
causes bronchial 
remodelling and it can be 
carcinogenic 
 
WHO Air Quality 
Guideline 
-PM2.5: 10 µg/m
3 annual 
mean and 25 µg/m3 daily 
mean 
-PM10: 20 µg/m
3 annual 
mean and 50 µg/m3 daily 
mean 
 
South African National 
Ambient Air Quality 
Standards (SA-NAAQS) 
-PM2.5: 20 µg/m
3 annual 
mean and 40µg/m3 daily 
mean 
-PM10: 40 µg/m
3 annual 
mean and 75 µg/m3 daily 
mean 
 
Sulphur Dioxide (SO2) Fossil fuel combustion at 
power plants and other 
industrial facilities, 
extraction of metal ore, 
burning of high sulphur 
containing fuels by 
vehicles, large ships and 
non-road equipment 
-Precursor to acid rain 
which results in 
deforestation 
-Reduces cardiac vagal 
tone and increases 
susceptibility to 
arrhythmias 
-Irritant to eyes, nose, 
throat and respiratory 
tract  
WHO Air Quality 
Guideline 
-500 µg/m3 over 10-
minute mean duration 
-20 µg/m3 over 24 hours 
 
South African National 
Ambient Air Quality 
Standards (SA-NAAQS) 
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- Causes cough and 
facilitates 
bronchoconstriction 
 
-500 µg/m3 over 10-
minute mean duration 
-125 µg/m3 over 24 hours 
 
Nitrogen Dioxide (NO2) Combustion processes used 
in generating power, 
heating, ships and vehicles 
-Plays a primary role in 
the formation of ozone 
-Impairs gaseous 
exchange and increases 
myocardial stress 
-Increases bronchial 
reactivity and 
susceptibility to 
respiratory infections 
 
WHO Air Quality 
Guideline 
-1-hour average of 200 
µg/m3  
- 40 µg/m3 annual 
average 
 
South African National 
Ambient Air Quality 
Standards (SA-NAAQS 
-1 hour average of 200 
µg/m3  
- annual average of 40 
µg/m3  
 
Ozone (O3) Troposphere -Formed by 
photochemical reactions 
in the presence of 
precursor pollutants such 
as Nitrogen Oxides and 
Volatile Organic 
Compounds 
-Depicts seasonal and 
diurnal patterns with 
higher concentrations in 
summer and in the 
afternoon (due to its 
photochemical origin) 
-Impairs gaseous 
exchange and increases 
myocardial stress 
-Induces Respiratory 
tract mucosal 
inflammation 
 
WHO Air Quality 
Guideline 
-8-hour average of 100 
µg/m3 per day 
 
South African National 
Ambient Air Quality 
Standards (SA-NAAQS 
-8-hour average of 
120ug/m3 per day 
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Carbon Monoxide (CO) Gas stoves, wood stoves, 
fireplaces and vehicles 
 -Reduces oxygen 
delivery to the body’s 
organs 
Acute exposure has been 
associated with headache, 
dizziness on exertion, 
nausea and mental 
confusion 
-Chronic exposure has 
been associated with flu 
like symptoms, 
unconsciousness and 
death 
Environmental Protection 
Agency Ambient Air 
Quality Standards  
-8-hour average of 9ppm 
-1-hour average of 
35ppm 
 
South African National 
Ambient Air Quality 
Standards (SA-NAAQS 
-8-hour average of 
8.7ppm 
-1 hour average of 
26ppm 
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2. LITERATURE REVIEW 
2.1 Objective of Literature Review 
The literature review will summarise the findings of various epidemiological studies 
conducted internationally and in Africa investigating the relationship between air pollutants 
and various cardiorespiratory outcomes. The rationale is to determine the current state of 
evidence and identify gaps in the literature in terms of methodological approaches used to 
determine the association between ambient air pollution and cardiorespiratory outcomes in 
adults. 
2.2 Search strategy 
Selection criteria included peer-reviewed primary research articles aimed at exploring the 
association between ambient air pollution cardiorespiratory outcomes using epidemiological 
study designs. Subject-specific databases (such as Medline through PubMed; CINAHL; 
Highwire; and the Cochrane library) were searched using keywords combined by Boolean 
operators such as ‘AND/ OR’ commands. Keywords were identifying using the PICO 
(Population-Intervention-Comparison-Outcome) acronym and Medical Subject Headings 
(MeSH terms). The first stage of literature search was a broad search strategy with the query: 
‘Ambient AND Air pollution AND Cardiovascular OR Respiratory AND Disease’. 
Furthemore, a second search with the following query was performed: ‘Ambient AND Air 
pollution AND Cardiovascular OR Respiratory AND Disease’.  This was followed by a more 
specific search including all elements of the selection criteria and different MeSH terms to 
narrow-down the search with the query; ‘((Ambient air pollution OR Particulate Matter OR 
Sulphur dioxide OR Carbon monoxide OR Nitrogen dioxide) AND (Cardiovascular OR 
Respiratory) AND (Disease) AND Humans[Mesh]’. Furthermore, the reference lists of 
articles found during the electronic search were used to obtain more articles. 
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2.3 Ambient air pollution and cardiovascular disease 
2.3.1 History of epidemiological association between ambient air pollution and 
cardiovascular disease 
The association between air pollution and disease can be dated back to the early 20th century 
where winter episodes had been known to be associated with increased cardiovascular 
mortality 23, 24. Since then, a multitude of epidemiological studies have been published 
investigating this relationship.  
2.3.2 Cardiovascular Health Outcomes of chronic ambient air pollution effects 
The Harvard Six Cities study, a prospective cohort study involving 8111 adults, showed that 
the overall mortality rate ratio for adults living in the most polluted versus the least polluted 
city was 1.26 (95% CI 1.08 to 1.47). Furthermore, deaths attributed to cardiovascular causes 
accounted for the largest category of increased mortality25. These results were reinforced by 
analysis of data from the ACS Cancer Prevention 2 study26. A follow up of this study found 
that a 10µg/m3 increase in annual PM2.5 mean concentration was shown to be associated with 
a 6% increase in cardiopulmonary mortality27. Similarly, in Seoul, a 10 µg/m3 increase in 
PM2.5 was found to be associated with a 1.36 (95%CI 1.11 to 1.66) increased risk of 
cardiovascular related deaths and an interquartile increase in SO2 was found to be associated 
with 1.50(95%CI 1.14 to 1.96) increased risk of cardiovascular attributable deaths 28 
Analysis of air pollutant exposure and blood pressure readings of adult Americans 57 years 
and older enrolled in the National Social Life, Health and Ageing project found that a 
3.91µg/m3 increase in yearly PM2.5 was associated with a 1.24(95%CI 1.11 to 1.38) increase 
prevalence odds of hypertension 29. Similar findings were found in Taiwan where a 10µg/m3 
increase in PM2.5 was found to be associated with a 0.45mmHg (95%CI 0.40 to 0.50), 
0.07mmHg (95CI 0.04 to 0.11) and 0.38(95% CI 0.33 to 0.42) increase in systolic blood 
pressure, diastolic blood pressure and pulse pressure respectively. Furthermore, each 10µg/m3 
increase in 2-year average PM2.5 was found to increase one’s risk of developing hypertension 
by 3% (hazard ratio = 1.03, 95% CI 1.01 to 1.05) 30.  
2.3.3 Cardiovascular Health Outcomes of acute ambient air pollution effects 
The NMAPS study conducted in the United States of America found that a 10µg/m3 increase 
in PM10 was associated with a 0.31% (95%CI 0.22% to 0.40%) increase in cardiopulmonary 
mortality31. This association was stronger in the APHEA-2 study where a 10µg/m3 increase in 
PM10 was found to be associated with a 0.69% (95% CI 0.31% to 1.08%) increase in 
cardiovascular mortality 32. Similar results were reported in various studies conducted across 
Asia: a study conducted in thirteen Japanese cities found that a 10µg/m3 increase in PM2.5 
was associated with a 1.0091 (95% CI 1.0057 to 1.0125) increase in cardiovascular 
mortality33; a multicity study involving four Chinese cities found that a 10µg/m3 increase in 
PM10 was associated with a 0.58% (95%CI 0.22 to 0.93) excess risk of cardiovascular 
mortality 34 and studies conducted in Hong Kong and Beijing found that a 10µg/m3 increase 
in PM10 and PM2.5 were associated with a 0.58%(95%CI 0.14% to 1.03%) and 0.39% (95%CI 
0.21% to 0.59%) increase in cardiovascular related mortality respectively 35,36. Moreover, 
results from a time series study conducted in Shanghai showed that an increase of 10µg/m3 in 
PM10 , SO2 and NO2 corresponded to a 1.008(95%CI 1.000 to 1.016), 1.017(95%CI 0.998 to 
1.036) and 1.029(95%CI 1.001 to 1.057) relative risk of stroke mortality respectively. 
However, in multipollutant models, the effects were weakened and were non-significant 37 
As part of the APHEA project, a study conducted in Europe involving eight European cities 
found that a 10µg/m3 increase in PM10 was associated with a 0.5% (95% CI 0.2% to 0.8%) 
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increase in hospital admissions attributed to cardiovascular causes 38. Similarly studies 
conducted in China and Iran found that a 10µg/m3 increase in PM10 was associated with a 
1.008(95%CI0.997 to 1.020) and 1.007(95%CI 1.001 to 1.012) increase in risk of 
cardiovascular related hospital admissions and a 10 µg/m3 increase NO2 was associated with 
1.014(95%CI 1.003 to 1.024) and 1.033(95% 1.010 to 1.055) increased risk of cardiovascular 
related hospital admissions 39,40.Moreover, in Italy, a 10µg/m3 increase in PM10 and PM2.5 
were associated with a 1.4%(95CI 0.7% to 2.3%) and 3%(95%CI .47% to 4.7%) increase in 
emergency hospital visits due to atrial fibrillation respectively and in Beijing a 10µg/m3 
increase in PM2.5 was found to be associated with up to a 0.74%(95%CI 0.27% to 1.22%) 
increase in angina related hospital visits 41, 42. 
Air pollution has also been shown to influence self-reported morbidity. A study conducted in 
Eastern Estonia found that an interquartile increase in PM2.5 was associated with a 
1.13(95%CI 1.02 to 1.26) increased odds of self-reported chest pain 43. In the United States of 
America, a 10µg/m3 increase in PM2.5 was found to be associated with a 1.05(95%CI 1.00 to 
1.10) and 1.08(95%CI 1.00 to 1.16) increased odds of self-reported hypertension and heart 
disease respectively44. Conversely, a study conducted in Australia investigating the 
relationship between NO2 and self-reported disease and symptoms found non-significant 
associations between increased levels of NO2 and self-reported hypertension, stroke, heart 
disease, chest pain and palpitations 45. 
2.3.4 Ambient air pollution and cardiovascular disease in Africa 
Ghana and South Africa were included in the World Health Organisation Study on Global 
Ageing and Adult Health. Analysis of data from the study found that there was a 1.13(95%CI 
1.05 to 1.22) increased odds of stroke with each 10µg/m3 increase in PM2.5 
46. In addition, in 
South Africa, an interquartile (12µg/m3) increase in PM10 was also found to be associated 
with a 4.1%(95%CI 0.4 to 8.1) increased risk of mortality attributed to cerebrovascular 
causes and a 12mg/m3 increase in NO2 was found to be associated with a 3.4%(95%CI 0.3 to 
6.6) and 8%(95%CI 2.9% to 13,4%) increased risk of mortality attributed to cardiovascular 
and cerebrovascular diseases respectively47. Furthermore, in Algeria, it was found that 
decreasing PM10 annual mean by 5µg/m
3 would avoid 3 cardiac hospitalisations 48 
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2.4 Ambient air pollution and respiratory disease 
2.4.1 Epidemiological association between ambient air pollution and respiratory disease 
Various epidemiological studies have also demonstrated associations between the above-
mentioned air pollutant and the respiratory system.22 
2.4.2 Ambient air pollution and lung function 
The ESCAPE study, a multi-centre cohort study conducted amongst adult Europeans found 
that a 10µg/m3 increase in NO2 exposure was associated with lower levels of FEV1 and FVC: 
-14.0 mL (95%CI -25.8 to -2.1) and -14.9 ml (95% CI -28/7 to -1.1) respectively. 
Furthermore, a 10µg/m3 increase in PM10 was also associated with lower levels of FEV1 and 
FVC: -44.6mL (95%CI -85.4 to -3.8) and -59.0mL (95%CI -112.3 to -5.6)49. A study 
investigating the relationship between exposure to chronic air pollution and adult lung 
function conducted by Forbes et al found that a 10µg/m3 increase in PM10, NO2, SO2 and O3 
were associated with a -92 mL (95%CI -129 to -55), -22 mL (95%CI -31 to -14), -22 mL 
(95%CI -36 to -7) and -4mL(95%CI, -26 to 19) change in FEV1 respectively and in 
Switzerland, a 10 µg/m3 increase in PM10, NO2, SO2 and O3 was found to be associated with 
a -1.59 mL, -1.24 mL,-0.70 mL and 0.70 mL change in FEV1(P value: <0.001,<0.001,<0.001 
and <0.01 respectively)50,51. Similarly, in Korea, a 10µg/m3 increase in PM10 was found to be 
associated with a -0.39 L/min (95%CI, -0.63 to -0.14) change in PEFR52.  
Moreover, a crossover study conducted in London amongst adult asthmatics found that 2 
hour exposure to a street with higher levels of particulate matter, elemental carbon and 
nitrogen dioxide reduced one’s FEV1 and FVC by 6.1% and 5.4% (p value 0.04 and 0.01) and 
a study investigating the association between traffic exposure and lung function found an 
inverse relationship between traffic density and lung function: relative to the lowest quartile 
of traffic density, the adjusted differences across increasing quartile were 5.1 mL(95%CI,-
21.7 to 31.9), -15.4 mL (95%CI,-42.3 to 11.5) and -21.5 mL (95%CI,-48.5 to 5.5) for FEV1 
and 1.2 mL (95%CI,-30.4 to 32.7), -23.4 mL (95%CI,-55.0 to 8.2) and -34.8 mL (95%CI-
66.5 to -3.1) for FVC respectively 53,54. Similarly, a study conducted in Tokyo among adult 
females found that after stratifying females into three groups according to traffic pollution 
exposure, the annual mean change in FEV1 was greatest in group 1 (highest exposure to 
suspended particulate matter and nitrogen dioxide: -0.020L/year) and lowest in group 
3(lowest exposure to suspended particulate matter and nitrogen dioxide: -0.009L/year). 
Group 2 (second highest exposure to suspended particulate matter and nitrogen dioxide) had 
a -.015L/year change in annual mean FEV1. The trend test thus showed that the higher the 
level of air pollution, the more significantly the FEV1 was reduced (p <0.001)
55. 
The inverse relationship between air pollution and lung function has also been depicted in 
children56.  
2.4.3 Ambient air pollution and asthma 
A vast number of epidemiological studies have investigated the impact of ambient air 
pollution on asthma. A cross sectional study conducted in Taiwan amongst 32672 school 
children found that a 10ppb increase in O3 was associated with a 1.138(95CI 1.001 to 1.293) 
odds of physician diagnosed asthma. Increasing levels of SO2 and PM10 were however 
associated with decreased odds of physician diagnosed asthma and increasing levels of NO2 
was associated with a non-significant change in physician diagnosed asthma 57. Similarly, in 
Oslo Norway, an interquartile increase in NO2 was associated with 0.81 (95CI 0.85 to 1.02) 
odds of asthma amongst 2871 children 58.  
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Conversely, a multitude of epidemiological studies have found significant associations 
between ambient air pollution and asthma. A cohort study conducted in Southern California 
amongst 3535 children found that the relative risk of developing asthma amongst children 
playing three or more sports was 3.3(95%CI 1.9 to 5.8) compared to children playing no 
sports59. The PIAMA study conducted in the Netherlands found that an interquartile increase 
in PM2.5 was associated with a 1.26(95%CI 1.04 to 1.51) and 1.28(95%CI 1.10 to 1.49) 
increased odds of prevalent and incident asthma respectively 60. Analysis of the data from the 
Tasmanian Longitudinal Health Study found that participants who did not have asthma at the 
age of 45 and lived less than 200 meters from a major road were 5.32(95%CI 1.07 to 25.4) 
times as likely to have asthma that persisted from age 50 to 53 years compared to participants 
who lived more than 200 meters from a major road61. 
2.4.4 Ambient air pollution and Chronic Obstructive Pulmonary Disease (COPD) 
A cross sectional study conducted among adult females in Germany found the following: 
living less than 100 meters from a major road was associated with a 1.79(95%CI 1.06 to 
3.02) odds of having COPD and an interquartile increase in NO2 and PM10 were associated 
with a 1.39(95%CI 1.20 to 1.63) and 1.37(95%CI 0.98 to 1.92) odds of having COPD 
respectively 62. Similarly, in Denmark, an interquartile range increase in NO2 was found to be 
associated with an 8%(95%CI 2 to 14)   increased risk of developing COPD and in Korea, a 
10µg/m3 increase in PM2.5 and NO2 were found to be associated with a 1.14(95%CI 1.00 to 
1.30) and 1.79(95%CI 1.02 to 3.13) odds of having COPD respectively 63, 64  
Several studies have demonstrated the association between ambient air pollution and COPD 
morbidity. Various studies conducted in Asia have assessed the relationship between ambient 
air pollution and COPD related hospital visits. In Beijing, an interquartile range increase in 
PM2.5 was found to be associated with a 2.38%(95%CI 2.22% to 2.53%) and 6.03%(95%CI 
5.19% to 6.87%) increase in daily COPD related out- and inpatient visits respectively 65. Also 
related, another Beijing study found that a 10µg/m3 increase in PM2.5 and PM10 was found to 
be associated with a 0.53%(95%CI 0.01 to 1.06 ) and 0.53%(95%CI 0.07% to 1.00%) 
increase in hospital admissions for acute exacerbation of COPD respectively66.Furthermore, 
in Hong Kong, a 10µg/m3 increase in SO2, NO2, O3,PM10 and PM2.5 was found to be 
associated with a 1.007(95ci 1.001 to 1.014), 1.026(95%CI 1.022 to 1.031) ,1.034(95%CI 
1.030 to 1.040), 1.024(95%CI 1.021 to 1.028) and 1.031(95%CI1.026 to 1.036) relative risk 
of hospital admissions for acute exacerbation of COPD67.Similar positive associations were 
depicted in the U.S where a 10µg/m3 increase in PM10 was found to be associated with a 
1.47%(95% CI 0.93 to 2.01) increase in COPD related  hospital admissions68. 
2.4.5 Ambient air pollution and Lung Cancer 
A study conducted in Guangzahou China found that PM2.5 contributed to 23.1% of the lung 
cancer burden in 2013 and in Alberta PM2.5 contributed to between 1.87% and 5.69% of 
incident lung cancer cases69. Several other studies have demonstrated associations between 
ambient air pollution and lung cancer 70.  
In Korea, a 10µg/m3 increase in PM10 and a 10ppb increase in NO2 was found to be 
associated with a 1.09(95%CI 0.96 to 1.23) and 1.10(95%CI 1.00 to 1.22) odds of lung 
cancer incidence respectively71.Furthermore, analysis of data from the Adventist Health and 
Smog Study-2 found that a 10µg/m3 increase in PM2.5 was associated with a 1.43 (95%CI 
1.11 to 1.84) risk  of developing lung cancer72.Analysis of data from the Canadian National 
Breast Screening Study found that a 10µg/m3 increase in PM2.5 was found to be associated 
with a 1.34(95%CI 1.10 to 1.65) risk of developing lung cancer73. These findings were 
reinforced by a meta-analysis conducted in China that found that a 10µg/m3 increase nitrogen 
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dioxide, nitrogen oxide, sulphur dioxide, and particulate matter was associated with a 
1.06(95%CI 0.99 to 1.13), 1.04(95%CI 1.01 to 1.07), 1.03(95%CI 1.02 to 1.05) and 
1.11(95%CI 1.00 to 1.22) odds of having lung cancer74. 
2.4.6 Ambient air Pollution and Lung Infection 
Various experimental studies have demonstrated that air pollutants impair respiratory 
immunity and these findings have been subsequently confirmed by various epidemiological 
studies75, 76, 77. A study conducted in Atlanta found that an interquartile increase in O3 and 
NO2 was associated with a 1.083(95%CI 1.038 to 1.131) and 1.025(95%CI 1.003 to 1.047) 
relative risk of being hospitalised for pneumonia amongst children between the ages of 0 and 
4. Furthermore, an interquartile range increase in these pollutants were associated with a 
1.041(95%CI 1.019 to 1.064) and 1.027(95%CI 1.016 to 1.039) relative risk of being 
hospitalised for upper respiratory tract infections78. In Vietnam, an interquartile increase in 
NO2 was found to be associated with 6.1%(95%CI 2.5% to 9.8%) increase in pneumonia 
hospital admissions amongst children between 0 and 1779.These findings have been 
reinforced by systematic reviews and meta-analysis that found that a 10µg/m3 in PM2.5 and 
PM10 were associated with a 1.8%(95%CI 0.5% to 3.1%) and 1.5%(95%CI 0.6% to 2.4%) 
excess risk of pneumonia hospitalisation respectively and a 10ppb increase in SO2, O3, and 
NO2 were found to be associated with a 2.9%(95% CI 0.4% to 5.3%), 1.7%(95% CI 0.5% to 
2.8%) and 1.4%(95%CI 0.4% to 2.4%) excess risk of pneumonia hospitalisation respectively 
80. 
Studies depicting associations between air pollution and respiratory infections have also been 
conducted in adults. A case crossover study conducted in Utah found that an interquartile 
increase in PM2.5 was associated with a 1.35(95%CI 1.06 to 1.80) odds of having pneumonia 
and in Rome, a 10µg/m3 increase in PM2.5 was found to be associated with a 2.8%(95%CI 
0.5% to 5.2%) increased risk of lower respiratory tract hospitalisation81, 82.  
2.4.7 Ambient air Pollution and Respiratory Symptoms 
In Eastern Estonia, an interquartile range increase in PM2.5 was found to be associated with a 
1.16(95%CI 1.03 to 1.31) and 1.33(95%CI 1.04 to 1.42) increased odds of self-reported 
shortness of breath and asthma attack respectively43. Furthermore, the RUPIOH study 
conducted in Europe amongst participants with asthma and COPD found that a 10µg/m3 
increase in PM10 was found to be associated with a 1.037(95%CI 1.002 to 1074) and 
1.027(95%CI 1.000 to 1.055) increased odds of self-reported shortness of breath and 
wheezing respectively83. Analysis of data from the SAPALDIA study found that amongst 
participants who had never smoked, a 10µg/m3 increase in PM10 was found to be associated 
with a 1.35(95%CI 1.11 to 1.65), 1.27(95%CI 1.08 to 1.50), 1.48(95%CI 1.23 to 1.78), 
1.33(95%CI 1.14 to 1.55)  and 1.32(95%CI 1.18 to 1.46) increased odds of chronic phlegm 
production, chronic cough or phlegm production, breathlessness during the day, 
breathlessness during the day or night and dyspnoea on exertion respectively and a study 
conducted in the Netherlands found that a 9.3 µg/m3 increase in soot and 17.6µg/m3 increase 
in NO2 was associated with a 5.3(95%CI 1.2 to 23) and 3.8(95CI 1.0 to 14) prevalence ratio 
of reporting phlegm84, 85. 
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2.4.8 Ambient air pollution and respiratory disease in Africa 
In South Africa, a 12mg/m3 increase in PM10 and 12mg/m
3 increase in NO2 were found to be 
associated with a 1.3%(95 CI, -1.4 to 4.0) and 2%(95%CI -1.6 to 5.7) increase in mortality 
attributable to respiratory diseases and cross sectional study conducted in Nigeria found a 
negative correlation between increasing levels of PM10 and lung function
47, 86. Furthermore, 
in Algeria, decreasing the annual PM10 by 5µg/m
3 reduced five hospitable admissions 
attributable to respiratory diseases and a study conducted in Namibia also found a significant 
association between particulate matter and episodes of coughing and phlegm 48,87. 
2.4.9 Review of studies investigating the relationship between ambient air pollution and 
cardiorespiratory disease in adults 
Table 2 summarises the findings 13 systematic reviews investigating the relationship between 
ambient air pollution and cardiorespiratory disease in adults.
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Table 2: Summary of systematic reviews investigating the relationship between ambient air pollutants and cardiorespiratory outcomes 
amongst adults 88-95 
Author Title Number of 
studies included 
Review Period Study 
Population 
Results Study Limitations 
Newell K, 
Kartsonaki C, 
Lam KBH, 
Kurmi O 
Cardiorespiratory 
health effects of 
gaseous ambient 
air pollution 
exposure in low- 
and middle-
income 
countries: a 
systematic 
review and meta-
analysis 
60 studies Studies from 
inception to 
2016 
Studies were 
included if they 
examined the 
cardiorespiratory 
effects of 
gaseous AAP 
(NOx, SO2, O 3 
and CO) in 
adults and were 
performed 
within LMICs 
 
% excess relative isk 
NOx 
 
• COPD 
motality – 
(1.11 – 2.51 
• COPD 
morbidity – 
2.48 (1.49 – 
3.46 
• Heart disease 
mortality – 
1.52 (0.98 – 
2.06) 
• Heart disease 
morbidity -
1.08 (0.73 – 
1.43) 
• Stroke 
mortality – 
1.01 (0.79 – 
1.24) 
• Stroke 
morbidity – 
0.95 (0.64 – 
1.26) 
• Significant 
heterogeinity 
of pooled 
estimates 
• Included 
studies made 
use of fixed 
site 
monitoring 
as an 
estimate of 
individual 
exposure to 
air pollutants 
• Only studies 
published in 
English were 
included  
• No studies 
conducted in 
Africa were 
included  
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• Respiatory 
mortality – 
0.86 (0.3 – 
1.38) 
• Respiratory 
morbidity – 
0.91 (0.34 – 
1.49) 
SO2 
• COPD 
mortaliy -  
1.68 (0.71 – 
2.64) 
• Heart disease 
mortality 1.31 
(0.82 – 1.81) 
• Heart disease 
mobidity  0.36 
(0.19 – 0.54) 
• Stroke 
mortality 0.64 
(0.53 – 0.76) 
• Stroke 
morbidity -  
0.23 (-0.06 – 
0.51) 
• Respiratory  
morbidity – 
1.64 (0.87 – 
2.40) 
O3 
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• Cardiovascular 
motality - -
0.01 (-0.33 – 
0.30) 
Song X, Liu Y, 
Hu Y, Zhao X, 
Tian J, Ding G, 
Wang S 
Short – Term 
Exposure to Air 
Pollution and 
Cardiac 
Arrhythmia: A 
Meta – Analysis 
and Systematic 
Review 
25 studies Studies from 
inception - 2015 
 Case-crossover 
and time-series 
studies were 
included if they 
evaluated the 
short-term (up to 
seven days) 
association 
between air 
pollutants 
(gaseous 
pollutants: 
carbon 
monoxide, 
nitrogen dioxide, 
sulfur dioxide, 
or ozone; 
particulate 
components: 
PM2.5 or PM10) 
and arrhythmia 
hospitalization 
or mortality 
Relative risk 
associated with a 10 
µg/m3 increase in 
PM2.5 and PM10, 
1ppm increase in CO 
and 10ppb increase in 
O3,NO2 and SO2 
Hospitalisation 
• PM2.5 – 1.018 
(1.005 – 
1.025) 
• PM10 – 1.010 
(1.004 – 
1.015) 
• CO – 1.060 
(1.017 – 
1.065) 
• O3 – 1.019 
(0.997 – 
1.035) 
• NO2 – 1.037 
(1.018 – 
1.055) 
• SO2 –1.018 
(1.000 – 
1.040) 
 
 
• Significant 
heterogeinity 
of pooled 
estimates 
• Included 
studies made 
use of fixed 
site 
monitoring 
as an 
estimate of 
individual 
exposure to 
air pollutants 
• No studies 
conducted in 
Africa were 
included  
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Mortality 
• PM2.5 – 1.027 
(0.987 – 
1.068) 
• PM10 – 1.009 
(0.994 – 
1.024) 
• CO – 1.077 
(0.790 – 
1.467) 
• O3 – 0.997 
(0.975 – 
1.018) 
• NO2 – 1.026 
(1.003 – 
1.050) 
• SO2 – 1.028 
(0.988 – 
1.069) 
Xialoe L, Hui 
L, Yanping R, 
Ruijuan L, 
Xiaogi Z, 
Michael R, 
Zhongjie F 
Association of 
Exposure to 
Particular Matter 
and Carotid 
Intima – Media 
Thickness: A 
Systematic 
Review and Meta 
- Analysis 
13 studies 1948 - 2015 population-
based studies, 
which not only 
reported the 
association 
between 
particular matter 
(PM2.5 or PM10) 
and CIMT, but 
also provided 
original data for 
particular matter 
(PM2.5 or PM10) 
10 µg/m3 increase in 
PM2.5 and PM10 was 
found to be associated 
with a 16.79 μm (95% 
CI, 4.95–28.63 μm) 
and 4.13 μm (95% CI, 
−5.79–14.04 μm) 
increase in carotid 
intima media 
thickness. 
• Significant 
heterogeinity 
of results 
• Included 
studies made 
use of fixed 
site 
monitoring 
as an 
estimate of 
individual 
exposure to 
air pollutants 
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and carotid 
artery intima-
media thickness 
• Only single 
pollutant 
effects 
assessed 
• No studies 
conducted in 
Africa were 
included  
 
Shah AS, Lee 
KK, McAllister 
DA et al 
Short term 
exposure to air 
pollution and 
stroke: 
systematic 
review and meta 
analysis 
103 studies 1948-2014 Studies 
investigatin the 
short term 
associations (up 
to a lag of seven 
days) between 
carbon 
monoxide, 
sulphur dioxide, 
nitrogen dioxide, 
ozone, and 
particulate 
matter 
PM2.5 (fine 
particles <2.5 
µm in size) or 
PM10 (coarse 
particles <10 µm 
in size) and 
admission to 
hospital for 
stroke or 
Relative risk 
associated with 
incemental increase in 
air pollutant 
• CO (1ppm ) : 
1.015 (1.004 – 
1.026) 
• SO2 (10ppb) : 
1.019 (1.011 – 
1.027) 
• NO2 (10 ppb) : 
1.014 (1.009 – 
1.019) 
• O3 (10 ppb) : 
1.001 (1.000 -
1.002) 
• PM2.5 (10 
µg/m3 ) : 
1.011 (1.011 – 
1.012) 
• PM10 (10 
µg/m3 ) : 
• Significant 
heterogeinity 
of results 
• Included 
studies made 
use of fixed 
site 
monitoring 
as an 
estimate of 
individual 
exposure to 
air pollutants 
• Only single 
pollutant 
effects 
assessed 
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mortality from 
stroke 
1.003 (1.002 – 
1.004) 
Shah AS, 
Langrish JP, 
Nair H et al 
Global 
association of air 
pollution and 
heart failure: a 
sytematic review 
and meta 
analysis 
35 studies 1948-2012 Peer reviewed 
original articles 
investigating the 
relationship 
between, carbon 
monoxide, 
sulphur dioxide, 
nitogen dioxide, 
ozone, 
particulate 
matter and 
reported heart 
failure 
hospitalisation 
or heart failure 
mortality 
 
  
% risk of heart failue 
hospialisation or 
mortality associated 
with incremental 
increase in air 
pollutants 
• CO (1 ppm ) : 
3.52 (2.52 – 
4.54) 
• SO2 (10 ppb) : 
2.36 (1.35 – 
3.38) 
• NO2 (10 
ppb) : 1.70 
(1.25 – 2.36) 
• O3 (10 ppb) : 
0.46 (-0.10 – 
1.02) 
• PM2.5 (10 
µg/m3 ) :2.12 
(1.42 – 2.82) 
• PM10 (10 
µg/m3 ) : 1.63 
(1.20 – 2.07) 
• Significant 
heterogeinity 
of pooled 
estimates 
• Only single 
pollutant 
effects 
assessed 
• No studies 
conducted in 
Africa were 
included  
 
Orellano P, 
Quaranta N, 
Reynoso J, 
Balbi B, 
Vasquez J 
Effect of outdoor 
air pollution on 
asthma 
exacerbation in 
children and 
adults: 
22 studies 2000 - 2016 Studies 
exploring the 
relationship 
between outdoor 
air pollution and 
acute 
Odds of asthma 
exacerbation wih an 
incremental increase 
air pollutant 
• Significant 
heterogeinity 
of pooled 
estimates 
• Only single 
pollutant 
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Systematic 
review and 
multilvel meta 
analysis 
exacerbations of 
asthma in 
children and 
adults through a 
case-crossover 
observational 
design.  
• SO2 (10ppb) : 
1.039 (0.988 – 
1.094) 
• PM10 (10 
µg/m3 ) : 
1.024 (0.995 – 
1.053) 
• NO2 (10ppb) : 
1.024 (1.005 – 
1.043) 
• PM2.5 (10 
µg/m3 ) : 
1.028 (1.009 – 
1.047) 
• CO (1ppm) : 
1.045 (1.005 – 
1.086) 
• O3 (1 ppb)  
1.032 (1.005 – 
1.060) 
effects 
assessed 
• Study 
findings 
cannot be 
extrapolated 
to lower 
income 
countries 
• No studies 
conducted in 
Africa were 
included  
 
Li J, Sun S, 
Tang R et al 
Major air 
pollutants and 
risk of COPD 
exacerpations: a 
systematic 
review and meta 
analysis 
59 studies 1946 - 2016  Studies 
investigating the 
association 
between major 
air pollutants 
and COPD 
exacerbation 
Relative risk 
associated with 
incremental increase 
in air pollutant 
• CO (100 
µg/m3 ) : 1.01 
(1.00 – 1.01) 
• SO2 (10 µg/m3 
) : 1.01 (1.00 – 
1.01) 
• Only single 
pollutant 
effects 
assessed 
• No studies 
conducted in 
Africa were 
included  
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• NO2 (10 µg/m3 
) : 1.04 (1.03 – 
1.06) 
• O3 (10 µg/m3 
) : 1.01 – 1.04) 
• PM2.5 (10 
µg/m3 ) : 1.02 
(1.01 – 1.04) 
• PM10 (10 
µg/m3 ) : 1.02 
(1.01 – 1.02)  
Moore E, 
Chatzidiakou L, 
Kuku MO et al 
Global 
Associations 
between Air 
Pollutants and 
Chronic 
Obstructive 
Pulmonary 
Disease 
Hospitalizations. 
A Systematic 
Review 
46 studies 1980 - 2015 Time series and 
case cross over 
studies assessing 
the effects of air 
pollution on 
COPD 
Odds of COPD 
hospitalisation 
assocciated with 
incremental increase 
in air pollutant 
• PM10 (10 
µg/m3 ) : 1.01 
(1.00 – 1.01) 
• O3(10 µg/m3 ) : 
1.02 (1.01 – 
1.03) 
• SO2 (10 
µg/m3 ) : 1.00 
(1.00 – 1.01 
• PM2.5 (10 
µg/m3) : 1.03 
(1.01 – 1.05) 
• CO (mg/m3) : 
1.02 (1.01 – 
1.03) 
• Significant 
heterogeinity 
of pooled 
estimates 
• Only single 
pollutant 
effects 
assessed 
• Included 
studies made 
use of fixed 
site 
monitoring 
as an 
estimate of 
individual 
exposure to 
air pollutants 
• No studies 
conducted in 
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• NO2 (10 
µg/m3 ) : 1.03 
(1.02 – 1.05) 
Africa were 
included  
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3. Conclusion 
The majority of epidemiological studies investigating the relationship between ambient air 
pollution and cardiorespiratory outcomes were conducted in America, Asia and Europe 
despite the majority of ambient air pollution related deaths occurring in lower- and middle-
income countries. Levels of air pollution and air pollutant composition on these continents 
differ from those found in Africa. Furthermore, the burden of disease in developed countries 
differs from those in developing countries and so various confounding factors present in 
developed countries and absent in developing countries could contribute to the above 
demonstrated associations. Moreover, majority of the studies made use of fixed site 
monitoring to assess each individual’s exposue to the various air pollutants and the 
interactive effects of pollutants on health were not investigated as evidenced by the reporting 
of results for single pollutant models. Multiple outcomes were also assessed in these studies. 
A common limitation in the African studies investigating the relationship between ambient 
air pollution and cardiovascular outcomes is the lack of accurate measurements representing 
each participant’s true exposure to the above-mentioned air pollutants and so the observed 
associations may not represent true associations between air pollution and cardiorespiratory 
outcomes.  Therefore, in the African context, further studies with more accurate exposure 
measurements should be conducted to contribute to the paucity of evidence available 
regarding the relationship between air pollution and cardiorespiratory outcomes. 
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ABSTRACT 
Background 
Many studies investigating the relationship between ambient air pollution and cardiorespiratory 
outcomes have been conducted in developed countries despite more vulnerable populations in 
low- and middle-income countries especially in Africa. No studies previous studies have been 
done in South Africa informal settlements. 
Aim 
The aim of the study was to investigate the relationship between ambient air pollutant exposure 
and self-reported cardiorespiratory outcomes amongst adults residing in four informal 
settlements of the Western Province of South Africa. 
Methods 
This cross-sectional study included 572 adults from four informal settlements (Khayelitsha, 
Marconi Beam, Oudtshoorn and Masiphumele) in the Western Cape, South Africa. The study 
made use of Land Use Regression to estimate each participant’s exposure to particulate matter 
of aerodynamic diameter of 2.5µm (PM2.5) and nitrogen dioxide (NO2). A questionnaire was 
adapted from the European Community Respiratory Health Survey and National Health and 
Nutrition Examination Survey questionnaire to collect data on self-reported cardiorespiratory 
outcomes and specific confounding factors of interest. 
Results 
The median age the participants was 39 years (Interquartile Range (IQR): 33 - 45) with 88.5% 
female. The median NO2 level was 22.4 µg/m
3 (IQR: 13.3 – 24.1) and the median PM2.5 level 
was 10.6 µg/m3 (IQR: 8.7 – 13.1). An increase of 10µg/m3 in annual NO2 level was found to 
be associated with a 2.9 (95%CI: 1.3 to 6.1) odds of having self-reported chest pain, adjusting 
for PM2.5 and confounders. No other significant association was found indicating an adverse 
health effect due to air pollution. 
Conclusion 
The study found preliminary circumstantial evidence of an association between annual ambient 
NO2 exposure and self-reported chest pain (a crude proxy of angina related pain), even at levels 
below both WHO Air Quality Guidelines and the South African National Ambient Air Quality 
Standards. However, the results should be interpreted cautiously due to the self-reported nature 
of the outcome measure and the cross-sectional design of the study. 
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1. Introduction 
In 2016, the World Health Organisation estimated that 4.2 million deaths were attributed to 
ambient air pollution1. The majority of deaths attributable to cardiovascular and respiratory 
disease1 were particulate matter (PM), sulphur dioxide (SO2), nitrogen dioxide (NO2) and 
ozone (O3)
2 and carbon monoxide (CO). 
Despite the majority of ambient air pollution related deaths occurring in low and middle income 
countries, most studies investigating the relationship between ambient air pollution and 
cardiorespiratory outcomes have been conducted in developed countries where air pollution 
levels and composition as well as population characteristics differ from those in Africa and 
more specifically in South Africa’s informal settlements1,4-11 . Furthermore, epidemiological 
studies conducted in Africa investigating this relationship have notable limitations including a 
lack of robust exposure measurements, lack of objective outcome measurements and 
inadequate adjustment of possible confounders12-16.  
There is therefore a paucity of robust data on the continent describing the relationship between 
ambient air pollution and cardiorespiratory outcomes, especially amongst adults residing in 
informal settlements. This study aimed to determine the relationship between PM2.5 and NO2 
exposure estimated using land use regression analysis and and self-reported cardiorespiratory 
outcomes amongst adults residing in four informal settlemts of the Western Province of South 
Africa. 
2. Methods and Materials 
2.1 Study design, population and sampling 
This study involved the analysis of a sub-set of data that was collected as part of a larger study 
conducted during 2015-2016 and investigating the effect of ambient air pollution on asthma 
among 590 primary school pupils in the Western Cape17. This sub-study used the cross-
sectional data from the baseline study conducted in 2015 investigating the association between 
ambient air pollution and cardiorespiratory outcomes among the caregivers of the child 
participants. The study areas included informal settlements in three areas prioritised in a needs 
analysis conducted by the department of Environmental Affairs and Development Planning 
(DEADP) in 2013. These areas included an urban industrialised area (Marconi Beam in 
Milnerton), a peri-urban area with a large informal sector (Khayelitsha) and a semi arid rural 
area (Oudtshoorn). An additional area (with a low air pollution score ranking) with comparable 
socio-economic status as the three identified areas was included (Mashiphumelele in 
Noordhoek). These areas were selected to maximise contrasts in exposure levels to the different 
ambient air pollutants.  
The sampling of child particpants are detailed elsewhere17. Briefly, a list of all the schools in 
the study area was obtained from the Department of Education and access to one or two schools 
per area was established. Approximately 150 students in each study area was selected.  
 
After meeting each school’s principal, obtaining permission from the school board and 
obtaining class lists and addresses, the houses of school children were visited by trained field 
staff to obtain the caregivers (parent or guardian) consent. Only those who consented were 
included in the study. The caregiver of these children who was at home at the time of the survey 
were selected for this study.  
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2.2 Questionnaire 
Trained interviewers administered the questionnaires to participants in their spoken language 
(English, Xhosa or Afrikaans). The principle investigator and study co-ordinator provided 
training on administration of the questionnaire to the fieldworkers.  The questionnaire was 
back-translated to ensure the consistency and reliability of the questionnaires. The use of 
mobile technology was implemented in the administration and capture of questionnaires. 
The questionnaire used for this study included items on: demographic characteristics, 
residential history, respiratory health, cardiovascular disease, blood pressure and other chronic 
illnesses such as high cholesterol, occupational history, exposure to indoor pollutants, exposure 
to outdoor pollutants, physical activity, psychosocial stress and tobacco use. 
 
The European Community Respiratory Health Survey18 and National Health and Nutrition 
Examination Survey questionnaire19 was incorporated into the study’s questionnaire. From 
these questionnaires the following cardio respiratory outcomes could be obtained: doctor 
diagnosis of asthma, wheezing in the last 12 months, shortness of breath in the last 12 months, 
woken up by feeling of tight chest in the last 12 months, attack of shortness of breath at rest in 
the last 12 months, attack shortness of breath after exercise in the last 12 months ,woken up by 
attack of shortness of breath in the last 12 months, bring up phlegm from chest at any time of 
day in the winter, woken up by heavy coughing at any time in the last 12 months, self- reported 
asthma, medication for asthma control, self-reported chest pain, self-reported hypertension and 
self-reported high cholesterol. An asthma symptom score was created from the responses to 8 
asthma questions: wheezing in last 12 months, shortness of breath in last 12 months, woken up 
by feeling of tight chest in the last 12 months, attack of shortness of breath at rest in the last 12 
months, attack of shortness of breath after exercise in the last 12 months, woken up by attack 
of breath in the last 12 months, self-reported asthma and medication for asthma control. A score 
of 1 was allocated for each positive response. 
2.3 Exposure Characterisation 
The annual average concentration of PM2.5 and NO2 was estimated at each participant’s address 
by land-use regression (LUR) models developed specifically for this study22. In brief, the air 
pollution monitoring campaigns were performed during 2015-2016 in each study area. Weekly 
measurements of PM2.5 and NO2 were performed in both winter and summer at 140 sites (40 
sites each in three study areas, and 20 sites in Masiphumulele) within a period of 1 year. These 
measurements were temporally adjusted using routinely monitored air quality measurements 
to obtain the seasonal (winter/summer) and annual averages. Predictors of exposure, obtained 
or collected on-site, such as household density, nearby traffic (e.g. major roads, bus stops, and 
train stations), waste burning sites, and land-use derived from geographic information system 
(GIS) were used to evaluate the spatial variation in the annual average concentrations. To 
maximize the adjusted explained variance, regression models were developed, using a 
supervised stepwise approach, and the models were validated using leave-one-out-cross-
validation (LOOCV). The LUR model was used to estimate annual average concentration of 
PM2.5 and NO2 for each participant’s address 
2.4 Statistical Analysis 
Data was captured, cleaned and analysed in Stata: Release 11 (StataCorp. 2009. Statistical 
Software. College Station, TX: StataCorp LP). Descriptive statistics was used to examine the 
characteristics of the study population, cardiorespiratory outcomes and various confounders. 
Bivariate regression was used to measure associations between various confounders and cardio 
respiratory outcomes. Confounders identified apriori and those with significant associations 
(p<0.15) were included in multi logistic regression models (Appendix D). Forward selection 
was then used to select the most parsimonious model. Collinearity of variables was assessed 
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by calculating the variable inflation factor and variables with an inflation factor greater than 10 
were removed from each model. Only variables decribed in literature to be associated with the 
outcome’s variables and those with a biological plausible relation to te outcome variables were 
included in the models to. Area was not adjusted for in the models as it did not improve the 
models in the sensitivity analysis. 
2.5 Ethical Considerations 
The main study was done in accordance with the Declaration of Helsinki of the 25th world 
Medical Assembly. The main study was approved by the University of Cape Town’s Research 
Ethics Committee (ethics number: 234/2009). The protocol for the sub study was approved by 
the University of Cape Town’s Research Ethics Committee (ethics number: 639/2018).  
 
53 
 
3. Results 
3.1 Demographic characteristics of the study participants 
Table 1 shows that most participants were female (93.0%) and that Mashiphumelele had the highest proportion of participants who had completed 
high school and were employed (86.6% and 51.8% respectively). The participants from Mashiphumelele were also younger (median age 36) than 
the participants from Khayelitsha (median age 39), Oudtshoorn (median age 41) and Marconi Beam (median age 37). isiXhosa was the predominant 
home language spoken amongst participants from Khayelitsha (87.2%), Marconi Beam (84.8%) and Mashiphumelele (97.3%) but not Oudtshoorn 
(20.5%). Villages in rural areas were the predominant place of birth of the participants (44.2%) and Mashiphumelele’s proportion of participants 
born in villages in rural areas (73.2%) was higher than Khayelitsha’s (50.0%) Oudstshoorn’s (1.9%) and Marconi Beam’s (62.1%). Most of the 
participants had never resided elsewhere before (77.6%). 
Table 1 Demographics and characteristics of the study participants 
 Khayelitsha 
(N = 172) 
n (%) 
Oudtshoorn 
(N = 156) 
n (%) 
Marconi Beam 
(N = 132) 
n (%) 
Mashiphumelele  
(N = 112) 
n (%) 
All areas 
(N = 572) 
n (%) 
Age (years) 
 
39 (33; 45) 41 (34; 49) 37 (31; 41) 36 (32; 43) 39 (33; 45) 
Gender (female) 
 
160 (93.0) 142 (91.0) 121 (91.7) 92 (82.14) 515 (90.0) 
Education 
 
Never attended school or only 
pre- school or primary school 
 
Completed High school 
 
 
35 (20.3) 
 
 
137 (79.7) 
 
 
45 (28.8) 
 
 
111 (71.2) 
 
 
24 (18.2) 
 
 
108 (81.8) 
 
 
 
15 (13.4) 
 
 
97 (86.6) 
 
 
119 (20.8) 
 
 
453 (79.2) 
Employed 78 (45.3) 50 (32.1) 59 (44.7) 58 (51.8) 245 (42.8) 
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Categorical variables depicted as number (%) 
Numerical variables depicted as median (25th percentile, 75th percentile) 
 
 
 
 
 
 
 
 
Home language 
Isixhosa 
Afrikaans, English or 
other 
 
150 (87.2) 
22 (12.8) 
 
32 (20.5) 
124 (79.5) 
 
112 (84.8) 
20 (15.2) 
 
109 (97.3) 
3 (2.7) 
 
403 (70.5)     
169 (29.6) 
 
Current Residence 
             Have lived elsewhere  
              
 
47 (27.3) 
 
 
23 (14.7) 
 
 
29 (22.0) 
 
 
29 (25.9) 
 
128 (22.4) 
 
Type of place of birth 
Farm 
Village in rural area 
Small town 
Suburb of a city 
Inner city 
 
10 (5.8) 
86 (50.0) 
20 (11.6) 
9 (5.2) 
47 (27.3) 
 
24 (15.4) 
3 (1.9) 
8 (62.8) 
0 (0) 
31 (19.9) 
 
4 (3.0) 
82 (62.1) 
14 (10.6) 
5 (3.8) 
27 (20.5) 
 
0 (0) 
82 (73.2) 
15 (13.4) 
1 (0.9) 
14 (12.5) 
 
38 (6.6) 
253 (44.2) 
147 (25.7) 
15 (2.6) 
119 (20.8) 
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3.2 Household characteristics of the study particpants 
Oudtshoorn had the highest proportion of participants who resided in brick houses (88.5%) compared to Khayelitsha (49.4%), Marconi Beam 
(54.6%) and Mashiphumelele (21.4%). The prevalence of air conditioning use was less than 5 percent across the study areas and none of the 
participants from Oudtshoorn had air conditioners in their homes. Although electricity was the predominant source of energy used across the study 
areas (97.2%), almost half (49.0%) of the participants also made use of paraffin for cooking and heating. Almost a third (31.1%) of the participants 
from Marconi Beam did not have a door or window that opened to the outside.  Khayelitsha had the highest proportion of participants who 
experienced water damage to their homes (22.1%) and the highest prevalence (16.9%) of participants who had intervened to reduce allergens in 
their homes. Participants residing in Oudtshorrn reported the highest proportion of pet ownership (44.9%).  
Table 2: Household characteristics of the study participants 
 
Khayelitsha 
(N = 172) 
n (%) 
Oudtshoorn 
(N = 156) 
n (%)     
Marconi Beam 
(N = 132) 
n (%) 
Mashiphumelele  
(N = 112) 
n (%) 
All areas 
(N = 572) 
n (%) 
      
House Type 
• Brick House 
• Shack 
• Other(Room in back yard, 
shack in backyard, Hut, 
Caravan, Wood house) 
 
85 (49.4) 
69 (40.1) 
18 (10.5) 
 
138 (88.5) 
6 (3.9) 
12 (7.7) 
 
72 (54.6) 
14 (10.6) 
46 (34.9) 
 
24 (21.4) 
33 (29.5) 
55 (49.1) 
 
319 (55.8) 
122 (21.3) 
131 (22.9) 
Air conditioning in home 
 
6 (3.5) 0 (0) 3 (2.3) 10 (8.9) 19 (3.3) 
Fuel used to heat house or 
cooking 
• Wood 
• Coal 
• Gas 
• Paraffin 
• Animal Dung 
• Solar energy 
 
 
4 (2.3) 
0 (0) 
28 (16.3) 
128 (74.4) 
0 (0) 
0 (0) 
 
 
 
6 (3.9) 
0 (0) 
16 (10.3) 
3 (1.9) 
0 (0) 
0 (0) 
 
 
 
0 (0) 
0 (0) 
4 (3.0) 
88 (66.7) 
0 (0) 
0 (0) 
 
 
 
0 (0) 
1 (0.9) 
4 (3.6) 
61 (54.5) 
0 (0) 
0 (0) 
 
 
 
10 (1.8) 
1 (0.2) 
52 (9.1) 
280 (49.0)       
0 (0) 
0 (0) 
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• Electricity 
 
166 (96.5) 149 (95.5) 131 (99.2) 110 (98.2) 556 (97.2) 
Door or window open while 
cooking 
Most of the time 
Some of the time 
Rarely (or only 
occasionally) 
Do not have a door or 
window that opens to the 
outside 
 
  
 
 
42 (24.4) 
91 (52.9) 
22 (12.8) 
 
17 (9.9) 
 
 
75 (48.1) 
88 (56.4) 
0 (0) 
 
0 (0) 
 
 
6 (4.6) 
58 (43.9) 
27 (20.5) 
 
41 (31.1) 
 
 
5 (4.5) 
64 (57.1) 
29 (25.9) 
 
14 (12.5) 
 
 
121 (21.2) 
301 (52.6) 
78 (13.6) 
 
72 (12.6) 
      
Sleep with open windows 
All of the time 
Sometimes 
 
 
31 (18.0) 
141 (83.0) 
 
60 (38.5) 
96 (61.5) 
 
22 (16.7) 
110 (83.3) 
 
41 (36.6) 
71 (63.4) 
 
154 (26.9) 
418 (73.1) 
Water damage to building or its 
content 
 
 
38 (22.1) 
 
3 (1.9) 
 
 
 
19 (14.4) 
 
14 (12.5) 
 
74 (12.9) 
 
Water damage in last 12 months 32 (18.6) 2 (1.3) 17 (12.9) 8 (7.1) 59 (10.3) 
Damp spots inside house in last 
12 months 
57 (33.1) 3 (1.9) 15 (11.4) 16 (14.3) 91 (15.9) 
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Categorical variables depicted as number (%) 
Numerical variables depicted as median (25th percentile, 75th percentile) 
 
 
 
 
 
 
 
 
 
 
 
 
Efforts done to reduce allergies 
Remove carpets, 
Bought a new carpet, 
Use anti dust mite sprays, 
Got rid of pets 
 
29 (16.9) 
 
 
2 (1.3) 
 
8 (6.1) 
 
 
 
5 (4.5) 
 
 
44 (7.7) 
 
 
Have Pets 
 
38 (22.1) 
 
70 (44.9) 15 (11.4) 
 
18 (16.1) 
 
141 (24.7) 
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3.3 Level of activity of the sudy participants 
Mashiphumelele had the greatest proportion of inactive participants (56.3%) who never walked a mile or more without stopping in the last month 
and 85.7% did no exercise in the preceding month compared to Khayelitsha - 44.8% never walked a mile or more without stopping in the last 
month and 77.9%% did no exercise in the preceding month. In Oudtshoorn, 16.7% never walked a mile or more without stopping in the last month 
and 81.4% did no exercise in the preceding month and in Marconi Beam 54.6% never walked a mile or more without stopping in the last month 
and 82.58% did no exercise in the preceding month).  
Table 3: Level of activity of the study participants 
 
 
 
 
 
 
 
 
 
 
 
 
Categorical variables depicted as number (%) 
Numerical variables depicted as median (25th percentile, 75th percentile) 
 
 Khayelitsha 
(N =172) 
n (%) 
Oudtshoorn 
(N = 156) 
n (%) 
Marconi Beam 
(N = 132) 
n (%) 
Mashiphumelele  
(N = 112) 
n (%) 
All areas 
(N = 572) 
n (%) 
 
Frequency of walking a mile or 
more without stopping in the last 
month 
Never 
At least once per month 
 
 
 
 
 
77 (44.8) 
95 (55.2) 
 
 
 
 
26 (16.7) 
130 (83.3) 
 
 
 
72 (54.6) 
60 (45.5) 
 
 
 
63 (56.3) 
49 (43.8) 
 
 
 
238 (41.6) 
334 (58.4) 
 
Exercise done in past month 
No exercise 
Exercised 
(jogging,cycling, 
swimming,aerobics, 
dancing,gardening,lift 
weights ) 
 
134 (77.9) 
38 (22.1) 
 
127 (81.41%) 
29 (18.59%) 
 
109 (82.6) 
23 (17.4) 
 
96 (85.7) 
16 (14.3) 
 
466 (81.5) 
106 (18.5) 
Number of times exercise per 
month (median p25 p75) 
3 (3 ,4) 
(n = 38) 
2 (2 ,3) 
(n = 29) 
3 (2 ,4) 
(n = 23) 
3 (2.5 ,4.5) 
(n = 16) 
3 (2,4) 
(n = 106) 
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3.4 Level of support and smoking habits of the study participants 
Oudtshoorn had the greatest proportion of participants receiving emotional (97.4%) and financial support (95.5%). Furthermore, the proportion of 
participants from Oudtshoorn (32.1%) who smoked cigarettes was greater than those from Khayelitsha (9.3%), Marconi Beam (2.3%) and 
Mashiphumelele (6.3%). The participants who smoked cigarettes, smoked a median of 6 cigarettes daily. 
Table 4: Level of support and smoking habits of the study participants 
 
 
 
 
 
 
 
 
 
 
   
Categorical variables depicted as number (%) 
Numerical variables depicted as median (25th percentile, 75th percentile) 
 
3.5 Cardiorespiratory outcomes of the study participants 
More than 5% of the participants reported having been diagnosed with asthma by doctor (6.6%). Khayelitsha had the greatest proportion of 
participants who reported having experienced wheezing (22.1%), shortness of breath (17.4%) and tight chest (12.8%). Mashiphumelele had the 
 Khayelitsha 
(N =172) 
n (%) 
Oudtshoorn 
(N = 156) 
n (%) 
Marconi Beam 
(N = 132) 
n (%) 
Mashiphumelele  
(N = 112) 
n (%) 
All areas 
(N = 572) 
n (%) 
Receiving Emotional Support 115 (66.9) 152 (97.4) 78 (59.1) 67 (59.8) 412 (72.0) 
Received emotional support 
within last 12 months 
165 (95.9) 142 (91.0) 125 (94.7) 109 (97.3) 541 (94.6) 
Receiving financial support 102 (59.3) 149 (95.5) 
 
58 (43.9) 55 (49.1) 364 (63.6) 
Smoke cigarettes 16 (9.3) 50 (32.1) 3 (2.3) 7 (6.3) 76 (13.3) 
Daily number of cigarettes 
smoked 
5 (3.5, 10) 
(n= 16) 
6.5 (4 ,15) 
(n = 50) 
4 (2 ,4) 
(n = 3) 
5 (2 ,5) 
(n = 5) 
6 (4 ,10) 
(n = 6) 
Number of years smoking 
 
12 (6.5 ,22) 
(n = 16) 
20 (13 ,28) 
(n = 50) 
20 (5, 40) 
(n = 3) 
15 (8, 18) 
(n = 5) 
17 (10 ,25) 
(n = 6) 
Pack years 3.4 (2.2 ,4.9) 
(n = 16) 
5.5 (3 ,15) 
(n = 50) 
4 (1 ,4) 
(n = 3) 
1.8 (1.2, 4.5) 
(n = 5) 
4.3 (2.6, 12.6) 
(n = 6) 
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greatest proportion of participants who reported having experienced shortness of breath after exercise (25.9%) and Khayelitsha’s and Oudtshoorn’s 
proportion of participants bringing up phlegm from the chest during winter (12.2% and 12.8% respectively) was greater than Marconi Beam’s 
(2.3%) and Mashiphumelele’s (8.9%). Furthermore, all the participants reported experiencing at least one asthma symptom in the preceding year. 
Khayelitsha had the highest prevalence of self-reported chest pain followed by Oudtshoorn with the prevalence in both areas above 10%.  
Khayelitsha also had the highest prevalence of hypertension and cholesterol (15.1%, 25.0% and 9.3% respectively). 
Table 5: Cardiorespiratory outcomes of the study participants 
 Khayelitsha 
(N =172 ) 
n (%) 
Oudtshoorn 
(N = 156) 
n (%) 
Marconi 
Beam 
(N = 132) 
 
n (%) 
Mashiphumelele  
 
(N = 112) 
 
n (%) 
All areas 
 
(n = 572) 
 
n (%) 
      
Doctor diagnosed asthma 14 (8.1) 11 (7.1) 7 (5.3) 6 (5.4) 38 (6.6) 
Wheezing in the last 12 months 38 (22.1) 20 (12.8) 13 (9.9) 21 (18.4) 92 (16.1) 
Shortness of breath in last 12 months 30 (17.4) 17 (10.9) 8 (6.1) 11 (9.8) 66 (11.5) 
Woken up by feeling of tight chest in the last 12 
months 
22 (12.8) 14 (9.0) 
 
9 (6.8) 9 (8.0) 
 
54 (9.4) 
Attack of shortness of breath at rest in the last 12 
months 
18 (10.5) 
 
14 (9.0) 
 
7 (5.3) 7 (6.3) 46 (8.0) 
Attack of shortness of breath after exercise in the last 
12 months 
35 (20.4) 26 (16.7) 14 (10.6) 29 (25.9) 104 (18.2) 
Woken up by attack of shortness of breath in the last 
12 months 
18 (10.5) 14 (9.0) 7 (5.3) 9 (8.0) 48 (8.4) 
Bring up phlegm from chest at any time of day in the 
winter 
21 (12.2) 20 (12.8) 3 (2.3) 10 (8.9) 53 (9.3) 
Woken up by heavy coughing at any time in the last 
12 months 
29 (16.9) 22 (14.1) 6 (4.6) 16 (14.3) 73 (12.8) 
Self-reported asthma 16 (9.3) 11 (7.1) 11 (8.3) 6 (5.4) 44 (7.7) 
Medication for asthma control 7 (4.1) 10 (6.4) 2 (1.5) 1 (0.9) 20 (3.5) 
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Asthma symptom score# 
• Score = 0 
• Score = 1 
• Score > 1 
 
0 (0) 
109 (63.4) 
63 (36.6) 
 
0 (0) 
123 (78.9) 
33 (21.2) 
 
0 (0) 
111 (84.1) 
21 (15.9) 
 
0 (0) 
75 (67.0) 
37 (33.0) 
 
0 (0) 
418 (73.1) 
154 (26.9) 
Affected by animals, dust or pollen from trees or 
flowers 
6 (3.5) 6 (3.9) 0 (0) 0 (0) 12 (2.1) 
Self-reported experience chest pain 26 (15.1) 17 (10.9) 5 (3.8) 4 (3.6) 52 (9.1) 
Self-reported hypertension 43 (25.0) 38 (24.4) 15 (11.4) 21 (18.8) 117 (20.5) 
Self-reported cholesterol 16 (9.3) 5 (3.2) 8 (6.1) 5 (4.5) 34 (5.9) 
#Asthma symptom score calculated as sum of: Wheezing in the last 12 months, Shortness of breath in last 12 months, woken up by feeling of tight chest in the last 12 months, Attack of shortness of breath at rest in the 
last 12 months, Attack of shortness of breath after exercise in the last 12 months, Woken up by attack of shortness of breath in the last 12 months, Self-reported asthma,  Medication for asthma control 
 
 
 
 
 
 
 
 
 
3.6 Summer, winter and annual levels of NO2 and PM2.5 
NO2 and PM2.5 levels were higher in winter (26.5µg/m
3 and 13.4µg/m3 respectively) than summer (13.7µg/m3 and 7.7µg/m3 respectively). The 
mean annual NO2 level was 20.5µg/m
3 and the mean annual PM2.5 level was 10.8µg/m
3. 
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Table 6: Descriptive summary of winter, summer and annual NO2 and PM2.5 levels estimated at households of the participants in the 
study areas using land-use regression modelling. 
 Min P25 P50 P75 Max Mean (95% CI) 
NO2 (summer) 2.4 4.4 16.8 18.3 35.8 13.7 (6.6-20.8) 
NO2 (winter) 17.7 19.2 28.6 30.1 44.4 26.5 (20.6 – 32.3) 
NO2 (annual) 12.5 13.3 22.4 24.1 39.9 20.5 (15.0 – 26.0) 
PM2.5 (summer) 0.1 5.4 8.1 9.6 16.7 7.7 (5.1-10.3) 
PM2.5 (winter) 2.2 10.1 12.9 17.2 26.6 13.4 (8.7-18.1) 
PM2.5 (annual) 4.3 8.7 10.6 13.1 28.0 10.8 (7.9-13.7) 
 
Min:   minimum P25: 25th percentile P50: median P75: 75th percentile Max: maximum 
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3.7 Association between NO2 levels and cardiorespiratory outcomes 
A 10µg/m3 increase in annual NO2 level was found to be significantly associated with a 2.9 
(95%CI: 1.3 to 6.1) odds of having self-reported chest pain in the two-pollutant model. 
Table 7:  Association between a 10µg/m3 increase in NO2 levels and cardiorespiratory 
outcomes (two-pollutant model) 
 
Outcome Odds Ratio 
Doctor diagnosis of asthma 1.0 (0.5-2.3)a 
Asthma-symptom score ≥ 2* 1.0 (0.6-1.5)b 
Self-reported chest pain 2.9 (1.3-6.1)c 
Self-reported hypertension 0.9 (0.5-1.6)d 
Self-reported high cholesterol 1.6 (0.7-3.6)e 
a: age, sex, smoke, affected by animals’ dust or pollen from trees or flowers 
b: age, sex smoke, brick house 
c: age, sex, smoke, active in past month, receiving emotional support, receiving financial support 
d: age, sex, smoke, active in past month, receiving emotional support, receiving financial support 
e: age, sex, smoke 
Bold text denotes statistical significance at p < 0.05 
*Asthma symptom score calculated as sum of: Wheezing in the last 12 months, Shortness of breath in last 12 months, woken up by feeling 
of tight chest in the last 12 months, Attack of shortness of breath at rest in the last 12 months, Attack of shortness of breath after exercise in 
the last 12 months, Woken up by attack of shortness of breath in the last 12 months, Self-reported asthma, Medication for asthma control 
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3.8 Association between PM2.5 levels and cardiorespiratory outcomes 
A 10µg/m3 increase in PM2.5 was found to be associated with a 0.4 odds  of having two or 
more asthma symptoms in the two-pollutant model. 
Table 8: Association between a 10ug/m3 increase in PM2.5 levels and cardiorespiratory 
outcomes (two-pollutant model) 
 
 
 
 
a: age, sex, smoke, born in town, affected by animals’ dust or pollen from trees or flowers 
b: age, sex, smoke, employed, damp spots inside house in last 12 months 
c: age, sex, smoke, active in past month, receiving emotional support, receiving financial support 
d: age, sex, smoke, receiving emotional support 
e: age, sex, smoke, receiving financial support 
Bold text denotes statistical significance at p < 0.05 
*Asthma symptom score calculated as sum of: Wheezing in the last 12 months, Shortness of breath in last 12 months, woken up by feeling 
of tight chest in the last 12 months, Attack of shortness of breath at rest in the last 12 months, Attack of shortness of breath after exercise in 
the last 12 months, Woken up by attack of shortness of breath in the last 12 months, Self-reported asthma, Attack of asthma in last 12 
months, Medication for asthma control 
 
 
 
 
 
Outcome Odds Ratio 
Doctor diagnosis of asthma 0.6 (0.1-2.7)a 
Asthma-symptom score ≥ 2* 0.4 (0.2-0.9)b 
Self-reported chest pain 0.5 (0.1-2.1)c 
Self-reported hypertension 1.0 (0.8-2.7)d 
Self-reported high cholesterol 0.4 (0.1-1.7)e 
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4. Discussion 
This cross-sectional study conducted amongst adults from four informal settlement in the Western Cape found a 
positive association between NO2 and the prevalence of self-reported chest pain (a surrogate for cardiovascular 
disease) adjusting for PM2.5 and other covariates.  Although no association was found between PM2.5 and 
cardiorespiratory outcomes in the current study, there is laboratory evidence suggestive of the role of PM2.5 in 
increasing the absorption and transport of NO2 into the human body, and thus resulting in a greater level of 
exposure to NO2 21. This is evident in the current study with the association between NO2  and self-reported 
chest pain increasing from an odds of 2.80 to 2.92, when PM2.5 was included in the model, suggestive of an 
adjunct effect of NO2 and PM2.5 on self-reported chest pain. 
 
The average annual NO2 estimated in all the four study areas were lower than the South African National 
Ambient Air Quality Standards (SAAQS) and the WHO Air Quality Guidelines of 40µg/m1, 22, 2. Thus the 
association of NO2 with self-reported chest pain was found at levels lower than SAAQS and WHO air quality 
guidelines. The average annual PM2.5 level of 10.01µg/m3 is lower than the South African National Ambient Air 
Quality Standards (SAAQS) of 25µg/m3 but was similar to the WHO Air Quality guideline of 10µg/m3 23,2. Thus, 
the lack of association between PM2.5 and cardiorespiratory outcomes and of NO2 with all cardiorespiratory 
outcomes except chest pain could thus be attributed to the fact that the pollutant levels were too low to exhibit 
hazardous effects. Furthermore, the sample size was also not powered enough to investigate the other 
associations, if indeed present.  
 
In this current study, a 10µg/m3 increase in NO2 was found to be associated with an almost three-fold increase 
in self-reported chest pain (OR: 2.92, 95% CI: 1.33 to 6.41). The number of significant associations were higher 
than what could be expected by chance for the number of comparisons made. A time-series study conducted in 
Canada amongst 157,028 adult participants found a 37.82µg/m3 increase in NO2 levels to be associated with a 
4% increased relative risk of having chest pain. The average NO2 level in the Canadian study (37.82µg/m3) was 
greater than the observed 20.51µg/m3 in the current study24. Furthermore, a cross-sectional study conducted 
amongst 26,991 women in Australia found no significant association between an interquartile range increase of 
6.02µg/m3 in NO2 () and chest pain (OR: 0.96, 99%CI 0.88 to 1.05)25. The current and Canadian study therefore 
suggest that NO2 can exert cardiovascular effects at levels lower than current local and international exposure 
limits. Furthermore, variables related to energy, transportation, and socio-economic factors have been shown to 
influence the association between NO2 and various outcomes26. The absence of adjustment for confounding 
variables such as household energy usage, transportation and socio-economic factors in the Canadian study could 
also explain the difference between effect size observed between the two studies. The lack of association between 
NO2 and PM2.5 and respiratory outcomes is not consistent with the results of studies conducted in Eastern 
Estonia, Namibia, and Europe 27,16,28,29. The low levels of air pollutants, lack of objective outcome measures and 
inadequate sample size in this study could explain explain the number of non-significant associations.  
 
According to the hygiene theory, children from rural areas or villages are exposed to more microbial substances 
which stimulate their immune systems and prevent them from developing asthma and other allergies later in life. 
Conversely, children born in urban areas are less exposed to these microbial substances and therefore have under 
stimulated immune systems in childhood which are hypersensitive and susceptible to various allergic disorders30. 
Furthermore, animal dander and cigarette smoke are known precipitants of asthma and sleeping with the window 
open could suggest increased exposure to outdoor air pollutants and pollen (precipitants of asthma)31,32. In the 
current study, demographic and household characteristics were therefore adjusted for in various models to 
mitigate the influence of residual confounding on the association between the air pollutants and respiratory 
outcomes. 
 
Land use regression (LUR) models were used to estimate each participant’s level of exposure to NO2 and PM2.5 
at the current address. The annual NO2 LUR model explained 76% of the spatial variability in the NO2 annual 
concentrations, 62% for the warm season and 77% for the cold season.  The annual PM2.5 LUR model explained 
29% of the spatial variability in the NO2 annual concentrations, 36% for the warm season and 29% for the cold 
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season20. The low spatial variation in PM2.5 could thus be an explanation for the lack of association between 
PM2.5 and the various cardiorespiratory outcomes as the observed measurements could be unrepresentative of 
each participant’s true exposure.  
 
The study had notable strengths. To the best of our knowledge, this is the only study conducted on the African 
continent using LUR modelling to determine the association between ambient air pollutants and cardio-
respiratory outcomes in adults. Furthermore, the findings from the study can contribute to the paucity of results 
on the African continent investigating health effects of ambient air pollution and thus give a more representative 
reporting of the global burden of disease due to ambient air pollution. In the case of self-reported chest pain, 
non-cardiac causes of chest pain have been previously described, but this misclassification of outcome is likely 
non-differential across the exposure spectrum and would have only driven the association towards the null, if 
present.  Furthermore, the cross-sectional nature of the study means that although inferences about associations 
can be made, the study cannot be used to make statements about causality and the fact that more than four fifths 
of the study paticipants were female, means that the observed associations could represent associations limited 
to females. 
 
6. Conclusion 
 
This study provided some preliminary evidence that exposure of adults to ambient NO2 levels increases the odds 
of self-reported cardiovascular morbidity (chest pain) at levels below the SAAQS and the WHO Air Quality 
Guidelines. The presence of an association below these standards and guidelines suggest a revision of the current 
legislation to protect vulnerable population, especially those from informal settlements who might have 
underlying vulnerability and are disproportionately affected by the burden of air pollution. However, it is 
important to conduct further research amongst these population using more objective outcome and longitudinal 
study designs. 
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PART D : APPENDICES 
Appendix A : Questionnaire 
 
Western Cape Air Pollution & Health Cohort Study 
 
Adult Questionnaire 
 
 
 
Cover sheet 
 
 
 
 
A1. Date ____/____/______                           A2. Study Identification No. ___________________ 
                 Day    Month    Year 
 
A3. Study Area _____________________________________ 
 
            
 
A4. Interview time started                               Time: _ _: _ _ am/pm 
 
A5. Interviewer: Enter gender of 
        respondent                                                  1 Male 2 Female 
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A. DEMOGRAPHICS 
 
 
A6. How old are you? 
 
_________years 
 
A7. What is your date of birth? 
 
 
_____/_____/_____ 
day        month        year 
9     Refused 
 
A8. Are you the Head of Household? 
 
1 Yes  2 No 
 
A9. What is your race? I’ll read the choices: 
 
1 African 
2 Indian 
3 Coloured 
4 White 
5 Other 
(SPECIFY:___________________) 
9 Refused 
 
 
 
 
A10. What is the highest grade or year of 
school you completed? [READ CHOICES] 
 
1 Never attended school or only pre-school 
2 Primary school 
3 High school 
4 Higher Education 
(College/Technikon/University) 
9 Refused 
 
A11. In which town, province and country were 
you born? 
 
___________; _____________, ___________ 
 town province country 
 
  A12. What is your home language?                           ___________________________________ 
   
A13. Are you employed?                                           1 Yes  2 No           
 
  A14. How much on average do you earn monthly?   __________________________________ 
 
  A15. How many people are working in this household? ________________________________ 
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B. RESIDENTIAL HISTORY 
  
A16. Where do you stay?                              ___________________________________ 
 
A17. Please list all the places that you have lived and the  
         number of years you lived there  
 
 
Places Years 
Philippi  
Khayelitsha  
Oudtshoorn  
Phoenix  
Joe Slovo  
Nyanga  
Milnerton  
Milnerton Ridge  
Others? __________________________________________  
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C. RESPIRATORY HEALTH 
 
I AM GOING TO ASK YOU SOME QUESTIONS. AT FIRST THESE WILL BE MOSTLY ABOUT 
YOUR BREATHING. WHEREVER POSSIBLE, I WOULD LIKE YOU TO ANSWER 'YES' OR 'NO'. 
 
 
A18. Have you had wheezing or whistling in your chest at any time in the last NO YES 
12 months? 
 
 
IF 'NO' GO TO QUESTION A19, IF 'YES': 
NO YES 
A18.1.Have you been at all breathless when the wheezing noise was present? 
 
 
A18.2. Have you had this wheezing or whistling when you did not have NO YES 
a cold? 
 
 
A19. Have you woken up with a feeling of tightness in your chest at any time in NO YES 
the last 12 months? 
 
 
A20. Have you had an attack of shortness of breath that came on during the day NO YES 
when you were at rest at any time in the last 12 months? 
 
 
A21. Have you had an attack of shortness of breath that came on following NO YES 
strenuous activity at any time in the last 12 months? 
 
 
A22.Have you been woken by an attack of shortness of breath at any time in theNO YES 
last 12 months? 
IF NO GO TO A23, IF YES 
A22.1 Have you been woken by an attack of shortness of breath in the NO YES 
last 3 months? 
IF NO GO TO A23, IF YES 
A22.1.1 On average have you been woken by an attack of shortness of NO YES 
breath at least once a week in the last 3 months? 
IF NO GO TO A23, IF YES 
A22.1.1.1How many times a week on average have you been TIMES 
woken by shortness of breath in the last 3 months? 
 
 
A23. Have you been woken by an attack of coughing at any time in the last 12 NO YES 
months? 
NO YES 
A24. Do you usually cough first thing in the morning in the winter? 
[IF DOUBTFUL, USE QUESTION A25.1 TO CONFIRM] 
 
 
NO YES 
A25. Do you usually cough during the day, or at night, in the winter? 
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IF 'NO' GO TO QUESTION A26, IF 'YES': 
A25.1 Do you cough like this on most days for as much as three months NO YES 
each year? 
 
 
A26. Do you usually bring up any phlegm from your chest first thing in the NO YES 
morning in the winter? 
[IF DOUBTFUL, USE QUESTION A27.1 TO CONFIRM] 
A27. Do you usually bring up any phlegm from your chest during the day, or NO YES 
at night, in the winter? 
 
 
IF 'NO' GO TO QUESTION 28, IF 'YES': 
A27.1 Do you bring up phlegm like this on most days for as much as three NO YES 
months each year? 
NO YES 
A28. Do you ever have trouble with your breathing? 
 
 
IF 'NO' GO TO QUESTIONA29, IF 'YES': 
A28.1 Do you have this trouble 
a) continuously so that your breathing is never quite right? 
b) repeatedly, but it always gets completely better? 
c) only rarely? 
 
 
TICK ONE BOX ONLY 
1 
2 
3 
 
 
A29. Are you disabled from walking by a condition other than heart or lung NO YES 
disease? 
 
 
IF 'YES' STATE CONDITION ____________________ AND GO TO QUESTION A30, 
IF 'NO': 
A29.1 Are you troubled by shortness of breath when hurrying on level NO YES 
ground or walking up a slight hill? 
 
 
IF 'NO' GO TO QUESTION A30, IF 'YES': 
A29.1.1 Do you get short of breath walking with other people of NO YES 
your own age on level ground? 
 
 
IF 'NO' GO TO QUESTION A30, IF 'YES': 
A29.1.1.1 Do you have to stop for breath when walking at NO YES 
your own pace on level ground? 
 
 
A30. FOR WOMEN ONLY - MEN GO TO A31 
Have you ever noticed that you had respiratory symptoms (such as wheeze, 
tightness in your chest or shortness of breath) at a particular time of your 
monthly cycle?  TICK ONE BOX ONLY 
yes, in the week before my period                                                 1 
yes, during my period 2 
yes, in the week after my period 3 
yes, another time of the month 4 
does not apply to me (i.e., amenorrhoeal) 5 
No 6 
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                                                                                                                                NO YES 
 
A31. Have you ever had asthma? 
 
IF 'NO' GO TO QUESTION A32, IF 'YES': 
 
 
NO YES 
A31.1 Was this confirmed by a doctor? 
YEARS 
A31.2 How old were you when you had your first attack of asthma? 
YEARS 
A31.3 How old were you when you had your most recent attack of asthma? 
 
 
 
A31.4.1-6 Which months of the year do you usually have attacks of asthma? 
NO YES 
A31.4.1 January / February 
A31.4.2 March / April  
A31.4.3 May / June  
A31.4.4 July / August 
A31.4.5 September / October 
A31.4.6 November / December 
NO YES 
A31.5 Have you had an attack of asthma in the last 12 months? 
IF NO GO TO A31.8, IF YES ATTACKS 
A31.6 How many attacks of asthma have you had in the last 12 months? 
ATTACKS 
A31.7 How many attacks of asthma have you had in the last 3 months? 
 
 
A31.8 How many times have you woken up because of your asthma in the 
last 3 months? TICK ONE BOX ONLY 
every night or almost every night                                               1 
more than once a week, but not most nights 2 
at least twice a month, but not more than once a week 3 
less than twice a month 4 
not at all 5 
 
 
A31.9. How often have you had trouble with your breathing because of your asthma 
in the last 3 months? TICK ONE BOX ONLY 
continuously                                                                      1 
about once a day 2 
at least once a week, but less than once a day 3 
less than once a week 4 
not at all 6 
 
 
NO YES 
A31.10 Are you currently taking any medicines including inhalers, 
aerosols or tablets for asthma? 
NO YES 
A31.11 Do you have a peak flow meter of your own? 
IF 'NO' GO TO QUESTION A31.12 , IF 'YES': 
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A31.11.1 How often have you used it over the last 3 months? TICK ONE BOX ONLY 
 
 
 
 
never 1 
some of the days 2 
most of the days 3 
 
 
A31.12 Do you have written instructions from your doctor on    NO YES 
how to manage your asthma if it gets worse or if you have an attack? 
 
 
A31.13 FOR WOMEN ONLY - MEN GO TO A32 
Have you ever noticed that your asthma got worse with your monthly 
cycle?  TICK ONE BOX ONLY 
Yes, in the week before my period                                                1 
Yes, during my period 2 
Yes, in the week after my period 3 
Yes, another time of the month 4 
Does not apply to me (i.e., amenorrhoeal) 5 
No 6 
 
 
 
    NO YES 
A31.14 Have you been pregnant (at least 25 weeks) since your asthma started? 
IF NO GO TO A32, IF YES 
A31.14.1.What happened to your asthma during your pregnancies? 
TICK ONE BOX ONLY 
got better 1 
got worse 2 
stayed the same 3 
not the same for all pregnancies 4 
don’t know 5 
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D. OCCUPATIONAL HISTORY 
 
I would now like to ask you some questions on the type of jobs that you have done. 
 
I am interested in each one of the jobs that you have done for more than 3 consecutive months since the 
time we last contacted you (as regards the follow-up). These jobs may be outside the house or at home, full 
time or part time, paid or not paid, including self-employment, for example in a family business. Please 
include part time jobs only if you had been doing them for more than 8 hours per week. 
 
 
A32. Are you currently 
 
 
Employed (including military service) 
Self employed 
Unemployed, looking for work 
Not working because of poor health 
Full-time house-person 
Full time student 
Retired 
Other 
 
 
TICK ONE BOX ONLY 
1 
2 
3 
4 
5 
6 
7 
8 
 
 
IF EMPLOYED OR SELF EMPLOYED OR A FULL TIME HOURSEPERSON GO TO A34 
 
 
A33. Have you been employed in any job for three continuous NO YES 
months or longer? 
 
 
IF YES NOW GO TO OCCUPATIONAL MATRIX 
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A34. If you had more than one job in the same company, or if you were doing more than one job at the same time, we would like to talk about them 
separately. Please start with your current or last job. 
 
 
A34.1. What is (was) the title of your 
JOB current (last) job? 
 
 
OCCUPATION 
 
 
JOB 1 
JOB 2 
JOB 3 
JOB 4 
JOB 5 
JOB 6 
JOB 7 
JOB 8 
JOB 9 
JOB 10 
A34.2. What did the firm, A34.3. In what month and A34.4. In what month and 
company or organisation do or year did you start working in year did you stop working in 
what services did it provide? this job? this job? 
INDUSTRY 
  MONTH YEAR         MONTH YEAR  
 
 
 
 
 
 
 
78 
 
 
 
 
 
NO YES 
A35. Have any of these jobs ever made your chest tight or wheezy? 
 
 
 
IF YES, (tick no or yes for each job) 
 
 
NO YES 
Job 1? 
 
   
Job 2? 
 
   
Job 3? 
 
   
Job 4? 
 
   
Job 5? 
 
   
Job 6? 
 
   
Job 7? 
 
   
Job 8? 
 
   
Job 9? 
 
   
Job 10? 
 
   
 
 
A36. Have you had to leave any of these jobs because they NO YES 
affected your breathing? 
 
 
IF YES, (tick no or yes for each job) 
NO YES 
Job 1? 
 
   
Job 2? 
 
   
Job 3? 
 
   
Job 4? 
 
   
Job 5? 
 
   
Job 6? 
 
   
Job 7? 
 
   
Job 8? 
 
   
Job 9? 
 
   
Job 10? 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
E. INDOORS EXPOSURES 
 
YEAR 
A37. When was your present home built? 
 
  A38. Which best describes the building in which you live?  
 
                     a) RDP house? 
b) a one family house detached from any other house? 
c) a one family house attached to one or more houses? 
d) a building for two families? 
e) a building for three or four families? 
f) a building for five or more families? 
h) an informal dwelling (shack) 
i) other: __________________________ 
 
 
TICK ONE BOX ONLY 
1 
2 
3 
4 
5 
6 
7 
8 
 
 
A39. How many years have you lived in your current home                             YEARS 
  
 
 
A40. Does your home have air conditioning? NO YES  
 
 
 
 
 
A41. Which of the following appliances do you use for heating or for hot water? 
NO YES 
A41.1 coal or wood fire 
A41.2 gas heater/stove 
A41.3 electric 
heater/stove 
 A41.4 wood 
heater/stove 
 A41.5 paraffin 
heater/stove  
A41.6 oil heater/stove 
A41.7 coal heater/stove 
A41.8 charcoal heater/stove 
A 41.9 Cattle manure/animal dung heater/stove 
A 41.10 Solar (sun) heater/stove 
 
A41.11 other: _____________________________________________________ 
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A42. What kind of stove do you mostly use for 
cooking?  
a) coal, coke, charcoal or wood (solid fuel)? 
b) gas ?  
c) electric? 
d) paraffin (kerosene)? 
e) oil? 
f) Cattle manure/animal dung? 
g) Solar (sun)? 
TICK ONE BOX ONLY  
 
 
                 1 
2 
3 
4 
5 
6 
 
h) other: _______________________________________________________ 7 
 
 
A42.1 IF YOU USE GAS FOR COOKING 
 
 
A42.1.1 gas hob 
A42.1 2 gas oven 
Which of the following do you have? 
NO YES 
 
 
 
A43. What kind of stove was mostly used for cooking in the home you lived 
in when you were five years old? TICK ONE BOX ONLY 
a) coal, coke or wood (solid fuel)?                                                                              1 
b) gas (gas from the mains)? 2 
c) electric? 3 
d) paraffin? 4 
e) gas (gas from bottles or other non-mains source) 5 
f) don’t know                                                                                                                6 
g) other: _______________________________________________________ 7 
 
 
 
MINUTES 
A44. On average how long have you spent cooking with your stove each day 
over the last four weeks? 
 
 
A45. Over the last four weeks when you were cooking did you have a door or window to the 
outside air open TICK ONE BOX ONLY 
a) most of the time 1 
b) some of time 2 
c) rarely (or only occasionally) 3 
d) I do not have a door or window that opens to the outside in my kitchen 4 
 
 
NO YES DK 
A46. Do you have an extractor fan over the cooker? 
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION A47, IF 'YES': 
A46.1 When cooking, do you use the fan TICK ONE BOX ONLY 
a) all of the time?                                                                           1 
b) some of the time? 2 
c) none of the time? 3 
 
 
NO YES DK 
A46.2 Does the fan take the fumes outside the house? 
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A47. Does the room which you use most at home during the day NO YES 
A47.1 have fitted carpets covering the whole floor? 
A47.2 contain rugs? 
 
A47.3 have double glazing windows? 
 
 
 
A48. How old is the oldest carpet or rug in the room which you use most at home 
during the day? , TICK ONE BOX ONLY 
a) less than one year                                                                                               1 
b) 1-5 years old 2 
c) more than 5 years old 3 
 
 
A49. On what floor is the room which you use most at home during the 
day? (The lowest floor of a building is 00) 
 
 
A50. Does your bedroom                                                                                           NO YES 
 
A50.1 have fitted carpets covering the whole floor?  
A50.2 contain rugs? 
A50.3 have double glazing? 
 
 
A51. How old is the oldest carpet or rug in your bedroom                            TICK ONE BOX ONLY 
            a) less than one year 
b) 1-5 years old 
c) more than 5 years old 
                                                                                                                      
                                                                                                                         TICK ONE BOX ONLY 
 
 
A52 How old is your mattress        
a) less than one year 
b) 1-5 years old 
c) more than 5 years old 
 
 
 
A53. What floor of the building is your bedroom on? (lowest=00) 
 
NO YES 
A54. Do you sleep with the windows open at night during winter? 
 
 
IF 'NO' GO TO QUESTION A55, IF 'YES': 
 
 
A54.1 Do you sleep with the windows open 
a) all of the time? 
b) sometimes? 
c) only occasionally? 
TICK ONE BOX ONLY 
1 
2 
3 
 
 
A55. Has there been any water 
damage to the building or its contents, 
NO
 
YES
 
DK for example, 
from broken pipes, 
leaks or floods? 
IF YES
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NO
 
YES
 
DK A55.1 Has there been any 
water damage in the last 12 
months 
 
 
A56. Within the last 12 months have you had wet or 
damp spots on surfaces 
inside your home other than in the 
basement (for example on walls, wall 
paper, NO
 
YES ceilings or carpets)? 
 
 
A57. Has there ever been any mould or 
mildew on any surface, other than
 
NO YES DK food, inside the home? 
IF 'NO' OR 'DON'T KNOW' GO TO 
QUESTION A58, IF 'YES': 
 
 
A57.1.1-6 Which rooms have been 
affected?
 
NO YES A57.1.1 bathroom(s) 
A
5
7
.
1
.
2 
b
e
d
r
o
o
m
(
s
) 
A
5
7
.
1
.
3 
l
i
v
i
n
g 
a
r
e
a
(
s
) 
A
5
7
.
1
.
4 
k
i
t
c
h
e
n 
A57.1.5 basement or attic 
 
A57.1.6 other: 
___________________________
____________________ 
 
 
A57.2 Has 
there been 
mould or 
mildew on any 
surfaces inside 
the home
 
NO YES in 
the last 12 
months? 
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F. OUTDOOR EXPOSURES 
 
‘This scale looks like a thermometer; it allows you to rate your personal 
opinion regarding the following question on annoyance from air pollution. You 
can indicate your level of annoyance on this scale between 0 and 10 where 
0 mean does not annoy at all' and 10 means intolerable annoyance.' 
 
 
A58. How much are you annoyed by outdoor air pollution (from traffic, industry, 
etc.) if you keep the windows open? 
 
 
 
intolerable annoyance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
doesn’t annoy at all 
 
 
 
 
 
   10 
 
 
   
9 
   
8 
   
7 
   
6 
   
5 
   
4 
   
3 
   
2 
   
1 
   
0 
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A59. How often do cars pass your house? 
a) constantly 
b) frequently 
c) seldom 
d) never 
 
 TICK ONE BOX ONLY  
1 
2 
3 
4 
A60. How often do heavy vehicles (e.g. trucks/buses) pass your house? TICK ONE BOX ONLY 
a) constantly                                                                                                                1 
b) frequently 2 
c) seldom 3 
d) never 4 
 
 
 
A61. Have you taken any of the following measures to reduce allergen or 
exposure to allergen in your home? NO YES 
A61.1 changed from carpet to a wooden or other smooth surface on 
floor of the room you use most 
 
A61.2 changed from carpet to a wooden or to a smooth surface on floor 
of your bedroom 
A61.3 bought a new carpet for the room you use most 
A61.4 bought a new carpet for your bedroom 
A61.5 used antidust-mite sprays 
 
A61.6 put an allergy-proof cover on your mattress 
A61.7 sold, given away or destroyed a pet dog or cat 
 
 
NO YES 
A62. Do you keep a cat? 
IF 'NO' GO TO QUESTION A63, IF 'YES' NO YES 
62.1 Is your cat (are your cats) allowed inside the house? 
62.2 Is your cat (are your cats) allowed in the bedroom? 
 
NO YES 
A63. Do you keep a dog? 
IF 'NO' GO TO QUESTION A64, IF 'YES': NO YES 
63.1 Is your dog (are your dogs) allowed inside the house? 
63.2 Is your dog (are your dogs) allowed in your bedroom? 
 
NO YES 
A64. Do you keep any birds? 
IF 'NO' GO TO QUESTION A65, IF 'YES': NO YES 
64.1 Are any of these birds kept inside the house? 
 
 
A65. Was there a cat in your home? 
A65.1 during your first year of life 
A65.2 when you were aged 1 to 4 years 
A65.3 when you were aged 5-15 years 
 
NO YES DK 
 
 
 
 
 
A66. Was there a dog in 
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your home? A66.1 during your 
first year of life 
A66.2 when you were aged 1 to 4 years 
A66.3 when you were aged 5-15 years 
 
 
A67. Was there a bird in your home? 
A67.1 during your first year of life 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A67.2 when you were aged 1 to 4 years 
A67.3 when you were aged 5-15 years 
NO YES DK 
 
 
 
 
 
NO YES DK 
A68. What term best describes the place you lived most of the time 
when you were under the age of five years? TICK ONE BOX ONLY 
a) farm                                                                                                              1 
b) village in a rural area 2 
c) small town 3 
d) suburb of a city 4 
e) inner city 5 
 
 
A69. When you are near animals, such as cats, dogs or horses, do you ever 
NO YES 
A69.1 start to cough? 
A69.2 start to wheeze? 
 
A69.3 get a feeling of tightness in your chest? 
A69.4 start to feel short of breath? 
A69.5 get a runny or stuffy nose or start to sneeze? 
A69.6 get itchy or watering eyes? 
 
 
A70. When you are in a dusty part of the house, or near pillows or duvets do you ever 
NO YES 
A70.1 start to cough? 
A70.2 start to wheeze? 
 
A70.3 get a feeling of tightness in your chest? 
A70.4 start to feel short of breath? 
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A70.5 get a runny or stuffy nose or start to sneeze? 
A70.6 get itchy or watering eyes? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A71. When you are near trees, grass or flowers, or when there is a lot of 
pollen about, do you ever 
NO YES 
A71.1 start to cough? 
A71.2 start to wheeze? 
A71.3 get a feeling of tightness in your chest? 
A71.4 start to feel short of breath? 
A71.5 get a runny or stuffy nose or start to sneeze? 
A71.6 get itchy or watering eyes? 
IF 'YES' TO ANY OF THE ABOVE: 
A71.7.1-4 Which time of year does this happen? NO YES 
A71.7.1 winter 
A71.7.2 spring 
A71.7.3 summer 
A71.7.4 autumn 
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G. CARDIOVASCULAR DISEASE 
 
A72. Have you ever had any pain or discomfort in your chest?  
 
YES  
   NO (GO TO A80) 
REFUSED (GO TO 
A80)  
DON'T KNOW (GO 
TO A80) 
 
 
A73. Do you get it when you walk uphill or hurry?  
 
 
YES   
NO (GO TO A79) 
NEVER WALKS UPHILL 
OR HURRIES  
REFUSED (GO TO A79)  
DON'T KNOW (GO TO 
A79) 
 
A74. Do you get it when you walk at an ordinary pace on level ground?  
 
 
YES  
NO  
REFUSED  
DON'T KNOW  
  
A75. What do you do if you get it while you are walking? Do you stop or slow down, or 
continue at the same pace?  
        
CODE "STOP OR SLOW DOWN" IF RESPONDENT CARRIES ON AFTER TAKING 
ISODIL (ISOSORBIDE DINITRATE).  
 
 
STOP OR SLOW DOWN   
CONTINUE AT THE SAME 
PACE (GO TO A79) 
REFUSED (GO TO A79) 
DON'T KNOW (GO TO A79) 
 
A76. If you stand still, what happens to it? Is the pain or discomfort relieved or not relieved?  
 
 
RELIEVED  
NOT RELIEVED (GO TO A79) 
REFUSED (GO TO A79) 
DON'T KNOW (GO TO A79) 
 
 
 
 
 
 
 
 
 
1 
2 
3 
7 
9 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
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A77. How soon is the pain relieved? Would you say …….. 
 
 
10 minutes or less or   
more than 10 minutes? (GO TO 
A79) 
REFUSED (GO TO A79) 
DON'T KNOW (GO TO A79)   
 
 
A78. Please look at this card and show me where the pain or discomfort is located.  
 
CODE ALL THAT APPLY.  
PROBE FOR ADDITIONAL AREAS.  
 
HAND CARD CDQ1  
 
 
 
1  
2  
3  
4  
5  
6  
7  
8  
REFUSED  
DON'T KNOW  
 
 
A79. Have you ever had a severe pain across the front of your chest lasting for half an hour or 
more?  
 
 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A80. Have you had shortness of breath either when hurrying on the level or walking up a 
slight hill?  
 
 
 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
 
 
 
 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
77 
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1 
2 
7 
9 
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YES  
NO  
REFUSED  
DON'T KNOW 
 
 
 
 
 
H. BLOOD PRESSURE 
 
A81. Have you ever been told by a doctor or other health professional that you had 
hypertension (hy-per-ten-shun), also called high blood pressure?  
 
IF HIGH BLOOD PRESSURE ONLY DURING PREGNANCY, CODE NO.  
 
INTERVIEWER INSTRUCTION: IF RESPONDENT SAYS “HIGH NORMAL BLOOD 
PRESSURE”, “BORDERLINE HYPERTENSION” OR “PREHYPERTENSION” CODE 
NO.  
 
 
 
YES 
NO (GO TO A86) 
REFUSED (GO TO A86)  
DON'T KNOW (GO TO A86)  
 
HELP SCREEN:  
Hypertension (High Blood Pressure): A repeatedly increased blood pressure with the first 
number 140 or higher and the second number 90 or higher. 
 
A82. Were you told on 2 or more different visits that you had hypertension (hy-per-ten-
shun), also called high blood pressure?   
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
 
A83. Hold were you when you were first told that you had hypertension or high 
blood pressure?  
 
   
  REFUSED  
DON'T KNOW 
 
 
A84. Because of your (high blood pressure/hypertension) (hy-per-ten-shun), have you ever 
been told to take prescribed medicine? 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1  
2  
7  
9  
 
 
 
 
1 
2 
7 
9 
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999 
90 
 
 
 
YES   
NO (GO TO A86)  
REFUSED (GO TO A86) 
DON'T KNOW (GO TO A86) 
 
 
 HELP SCREEN:  
Prescribed Medicine: Prescribed medicines are those ordered by a doctor or other health 
provider through a written or verbal prescription for a pharmacist to fill. Prescription 
medicines can also be given by a medical provider directly to a patient to take home, such as 
free samples. 
 
 
 
 
 
A85. Are you now taking a prescribed medicine? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A86. Did you take your blood pressure at home during the last 12 months? 
 
YES   
NO (GO TO A88) 
REFUSED (GO TO A88) 
DON'T KNOW (GO TO A88) 
 
A87. How often did you check your blood pressure at home during the last 12 months? (You 
can tell me the number of times per day, per week, per month, or per year.)                      
………………………………………. 
                                                                                                                 ENTER NUMBER OF 
TIMES 
   
  REFUSED (GO TO A88) 
DON'T KNOW (GO TO A88) 
 
.......................... 
ENTER UNITS 
 
PER DAY   
PER WEEK 
PER MONTH 
PER YEAR 
 
A88. Did a doctor or other health professional tell you to take your blood pressure at home? 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
7777 
9999 
 
 
 
 
1 
2 
7 
9 
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YES   
NO  
REFUSED  
DON'T KNOW 
 
A89. Have you ever been told by a doctor or other health professional that your blood 
cholesterol level was high? 
 
YES (GO TO A91)  
NO  
REFUSED  
DON'T KNOW 
 
 
 
 
 
I. OTHER CHRONIC CONDITIONS 
 
A90.  Have you ever had your blood cholesterol checked? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A91. Have you ever been told by a doctor or other health professional that you had diabetes? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A92. Have you ever been told by a doctor or other health professional that you had congestive 
heart failure? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A93. Have you ever been told by a doctor or other health professional that you had coronary 
heart disease? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
92 
 
A94. Have you ever been told by a doctor or other health professional that you had angina? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A95. Have you ever been told by a doctor or other health professional that you had heart 
attack (myocardial infarction? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A96. Have you ever been told by a doctor or other health professional that you had stroke? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A97. Have you ever been told by a doctor or other health professional that you had 
emphysema? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A98. Have you ever been told by a doctor or other health professional that you had thyroid? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
A99. Have you ever been told by a doctor or other health professional that you had chronic 
brochitis? 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
 
A100. Have you ever been told by a doctor or other health professional that you had 
tuberculosis? 
 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
 
 
 
 
1 
2 
7 
9 
93 
 
YES   
NO  
REFUSED  
DON'T KNOW 
 
 
 
 
J. PHYSICAL ACTIVITY 
 
A101. In the past month, how often did you 
walk a mile or more at a time without stopping? 
 
 
 
_______ times 1 day 
number 
per               2 week 
3 month 
0 never 
 
 
 
The next questions are about your leisure time physical activity during the past month. We are 
interested in the following exercises, sports, or physically active hobbies that you might have 
done. 
 A102. In the past month, did you do any 
physical activity such as jogging, cycling, 
swimming, aerobics, dancing, gardening or lift 
weights? 
 
1 Yes 
2 No [GO TO A108] 
 
If yes, what were these activities? 
 
How often did you participate in them? 
 A103. Activity 1: 
________________________________ 
 
 
_______ times 1 day 
number 
per               2 week 
3 month 
 
 
 
 
A104. Activity 2 
________________________________ 
 
 
 
 
 
_______ times 1 day 
number 
per               2 week 
3 month 
 
A105. Activity 3 
________________________________ 
 
 
_______ times 1 day 
number 
per               2 week 
3 month 
 
A106. Activity 4 
________________________________ 
 
 
_______ times 1 day 
number 
per               2 week 
3 month 
 
 
 
 
 
1 
2 
7 
9 
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A107. Activity 5 
________________________________ 
 
 
_______ times 1 day 
number 
per               2 week 
3 month 
 
A108. How does the amount of activity that 
you stated above for the past month compare 
with your physical activity for the past 12 
months? 
 
1 more active 
2 less active 
3 about the same 
8 don’t know 
 A109. Compared with yourself 10 years ago, 
would you say you were more or less active 
now? 
 
1 more active 
2 less active 
3 about the same 
8 don’t know 
  
 
 
 
 
 
 
K. PSYCHO-SOCIAL STRESS 
 
Now I would like to ask a few questions about your friends, family, home and work  
 
A110. Can you count on anyone to provide you with emotional support such as taking over 
problems or helping you make a difficult decision? 
 
YES   
NO (GO TO A112) 
DON’T NEED HELP (GO TO 
A112)  
REFUSED (GO TO A112) 
DON’T KNOW (GO TO A112) 
 
 
A111. In the last 12 months, could you have used more emotional support than you received? 
 
YES  
NO  
REFUSED  
DON’T KNOW  
 
A112. If you need some extra help financially, could you count on anyone to help; for 
example, by paying any bills, housing costs, hospital visits, or providing you with food and 
clothes? 
 
 
 
 
 
 
1 
2 
3 
7 
9 
 
 
 
 
1 
2 
7 
9 
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YES   
NO 
OFFERED HELP BUT I WOULDN’T 
ACCEEPT IT  
REFUSED 
DON’T KNOW 
 
 
A113. In the last 12 months, do you feel stressed at work? 
 
YES  
NO  
REFUSED  
DON’T KNOW  
 
 
 
 
 
 
L. TOBACCO USE 
Cigarette use 
 A114. Have you smoked at least 100 cigarettes 
during your entire life (equivalent to about 5 
packs)? 
 
1 Yes 
2 No [GO TO A126] 
 
A115. How old were you when you first 
started smoking cigarettes fairly regularly? 
 
______ Age In Years 
 
A116. Do you smoke cigarettes now? 
 
1 Yes 
2 No [GO TO A120] 
 A117. About how many cigarettes do 
you smoke per day? 
 
______ number 
 
A118. For approximately how many 
years have you smoked this amount? 
 
______ years 
 
A119. Was there ever a period of a year 
or more when you smoked more than 
[number in A117] cigarettes per day? 
 
1 Yes 
2 No 
 
A120. During the period when you were 
smoking the most, about how many 
cigarettes per day did you usually smoke? 
 
 
_______ 1 cigarettes per day 
number 2 packs per day 
 
0     less than 1 per day 
98 varied 
 A121. For how many years did you smoke 
that amount? 
 
 
________ years 
number 
 
A122. Have you ever quit smoking for a 
period of one year or longer? 
 
1 Yes 
2 No 
 
 
 
 
 
 
1 
2 
3 
7 
9 
 
 
 
 
1 
2 
7 
9 
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A123. Since you first started smoking; 
how many years altogether have you 
stayed off cigarettes? 
 
0 never quit smoking 
77 less than one year 
___________ years 
number 
 
A124. About how old were you when you 
last smoked cigarettes (fairly regularly)? 
 
________ 
age 
 
8 don’t know 
98     currently smoking [GO TO A127] 
 A125. About how many cigarettes per 
day did you usually smoke at that 
time? 
 
0     less than 1 per day 
 
_______ 1 cigarettes per day 
number 2 packs per day 
 
98 varied 
 A126. Did you quit smoking because you had a 
health problem that was caused or made worse 
by smoking? 
 
1 Yes 
2 No 
8 Don’t know 
 
Other Tobacco Use 
 A127. Have you ever smoked a pipe regularly? 
YES means more than 350grams of tobacco 
 
1 Yes 
2 No [GO TO A129] 
 
 
 
in a lifetime 
 
 
A128. How much pipe tobacco are you 
smoking now? [On the average over the 
entire time you smoked pipes, how many 
grams did you smoke per week?] 
 
___ grams per week 
 
 
 
 
 
Cigar Use 
 A129. Have you ever smoked cigars regularly? 
Yes means more than 1 cigar a week for a 
year 
 
1 Yes 
2 No [END] 
 
A130. On the average over the entire time 
you smoked cigars, how many cigars did 
you smoke per week? 
 
___ Cigars per week 
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THANK YOU FOR COMPLETING THIS QUESTIONNAIRE! 
 
 
 
 
END: Thank you for helping us! 
 
 
 
 
Interview completed at: Time: _ _:_ _ am / pm 
 
 
[INTERVIEWER: Indicate quality of interview 1 reliable 2 unreliable] 
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Appendix B: Informed Consent 
 
Consent to participate in a survey investigating cardiopulmonary health effects in 
adults due to exposures to ambient air pollution and other environmental pollutants in 
the Western Cape 
 
1. Title of research project 
 
An Epidemiological Cohort of Adult Investigating Cardiopulmonary Outcomes Following 
Exposure to Ambient Air Pollution and Other Environmental Pollutions 
 
2. Name of researchers 
 
             Mohamed  Aqiel Dalvie (BSc, Honours, MSc, PhD) 
             Mohamed Jeebhay (MbChB, MMED, PhD) 
             Rajen Naidoo (MbChB, MMED, PhD) 
             Toyib Adedamola Olaniyan (BSc Hons., MSc)                         
 
            Purpose of the research project 
 
The Department of Environmental Health and Development Planning, is conducting this 
survey investigating the effect of air pollution and other environmental pollutants on 
cardiopulmonary health in adults. This study is necessary and important because air pollution 
in the Western Cape is significant and could result in adverse health effects. We would like to 
interview you on your own health during this year (2016). The study will benefit residents in 
the Western Cape exposed to air pollution and other environmental pollutants. 
 
3. Description of the research project 
  
 We will interview you once at your home for about 15 minutes.  
             The testing will include: 
100 
 
 
a) Questionnaires:  A member of our study team will interview you in privacy to complete 
a questionnaire. You will be asked questions about your breathing or chest problems; 
current and previous employment history; smoking habit (if any); home environment; and 
questions on your use of medications and health services. 
 
4. Risks and discomforts of the research 
 
     There are minimal risks associated with completing the questionnaire. The only risk                                           
            is a loss of confidentiality about personal information but the data will be seen only 
by  
            study personnel.  All reports will present aggregate data in which individuals will not 
be        
            identifiable.   
 
6. Expected benefits to you and to others 
  
            If any questions are found through the questionnaire, then you will be referred to your 
practitioner or  
            local clinic for further management.  
 
The results of the study would help you and others know the risks associated with various 
occupational and environmental pollutions for adults. This would further allow you to 
manage and/or reduce your risk. A copy of the final report of the study will be made available 
at the school that your child attends as the school is part of the children study. Additionally, 
an information sheet on the risks of air pollution and how to manage these risks will be 
distributed to you. A seminar on the results of the study and the managing of the risks of air 
pollution will be held at the school after the completion of the study.    
The results obtained from this questionnaire at large would help the government of the 
Western Cape know the degree to which health is affected by environmental pollution. This 
would further help in further planning in reducing environmental exposures in residential 
areas. 
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7. Costs to you resulting from participation in the study 
 
The study is offered at no cost to you.  In the event a problem is discovered and you wish to 
be seen by a doctor for it, we can recommend to you who to see.  However, the study cannot 
pay for these additional medical visits or treatments. 
 
 
 
8. Confidentiality of information collected 
 
Your and your child’s name will not appear in any reports on this study. The records from the 
questionnaires will be kept completely confidential and will be seen only by members of the 
study team. 
 
9. Documentation of the consent  
 One copy of this signed document will be kept together with our research records for 
 this study. A copy of the information sheet about the study will be given to you to 
keep. 
 
10. Contact person.   
 
You may contact one of the following persons for answers to further questions about the 
research, your rights, or any injury you may feel is related to the study.   
 
            Name of person: MA Dalvie (The principal investigator)     telephone 021 4066610 
      Name of person: Lamees Emjedi (Ethics administrator)       telephone 021 4066492 
 
11.     Voluntary nature of participation 
 
    Your participation in this project is voluntary. Subsequent to your consent, you  
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    may refuse to participate in or withdraw from the study at any time without penalty or loss    
          of benefits to which you may otherwise be entitled.  
 
9. Consent of the participant 
  
I have read the information given above, or it has been read to me.  I understand the meaning 
of this information. By signing this form, I hereby consent to participate in the study.  I also 
understand that I am free to withdraw from the study at any time without penalty. 
 
 __________________________________ _____________________________ 
 Printed name of participant    Signature, Mark, or Thumb Print  
__________________________________  ______________________________ 
Interviewer’s name (Print)    Signature 
 
__________________________________  ______________________________ 
Witness (Print) (If caregiver is illiterate)               Signature 
 
 
 
 
DATE: ____________________ 
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Appendix C: Ethics approval letter 
 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sclences 
Human Research Ethics Committee 
Room E53-46 Old Main Buildin Groote Schuur Hosptti Observatory 792 
Telephone [021] 406 649 Emall: sumay.h.aflefdlen@uct.ac.z website:
 
 
29 October 2018 
HREC REF: 639/2018 
Prof A Dalvle 
School of Public Health & Famlly Medlcine Room 4.31, 4th Floor 
Falmouth Bullding FHS 
Dear Prof Dalvle 
PROJECT TITLE: AMBIENT AIR POLLUTION AND CARDIO RESPIRATORY OUTCOMES IN 
THE 
WESTERN CAPE IN 2016 (SUB-STUDY LINKED TO 234/2009) - Masters Candidate: Dr H 
Bagula 
Thank you for submittlng your study to the Faculty of Health Sclences Human Researth Ethlcs 
Commlttee (HREC) for review. 
It Is a pleasure to inform you that the HREC has formally approved the above-mentloned study. 
Approval Is granted for one year until the 30 November 2019. 
Please submit a progress form, using the standardlsed Annual Report Form Jf the study contlnues 
beyond the approval perlod. Please submit a Standard Closure form if the study Is completed wlthln 
the approval period. 
(Forms can be found on our website:  
We acknowledge that the student: Dr Herman Bagula will also be Involved In this study. 
Please quote the HREC REF In all your correspondence. 
Please note that the ongoing ethical conduct of the study remains the responslbillty of the principal 
investigator. 
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Please note that for all studles approved by the HREC, the prlnclpal Investigator obtain appropriate 
Instltutlonal approval, where necessary, before the research may occur. 
Yours sincerely 
Federal Wide Assurance Number: MA00001637. 
Institutional Review Board (IRB) number: IRB00001938 
This serves to confirm that the University of Cape Town Human Research Ethics Commlttee 
compiles to the Ethics Standards for Cllnlcal Research with a new drug In patients, based on the 
Medlcal Research Councll (MRC-SA), Food and Drug Administration (FDA-USA), International 
Conventlon on 
Harmonlsation Good Cllnical Practice (ICH GCP), South African Good Clinical Practice Guidellnes 
(Doy 2006), based on the Association of the British Pharmaceutical Industry Guidelines (ABPI), and 
Declaration of Helsinki (2013) guidelines. 
The Human Research Ethls Committee granting thls approval is in compliance wlth the ICH 
Harmonised Tripartlte Guidellnes E6: Note for Guidance on Good Cllnjcal Practice 
(CPMP/ICH/135/95) and FDA Code Federal Regulation Part 50, 56 and 312.
Signature removed
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Appendix D: Bivariate association between covariates and cardio respiratory outcomes 
 Doctors 
diagnosed 
asthma 
Asthma score Wheezing 
in the last 
12 months 
 
Shortness of breath 
in last 12 months 
Woken up by 
feeling of tight 
chest in the last 
12 months 
Attack of 
shortness of 
breath at rest 
in the last 12 
months 
 
Attack of 
shortness of 
breath after 
exercise in 
the last 12 
months 
 
Woken up by 
attack of 
shortness of 
breath in the 
last 12 
months 
 
Variable 
Name 
Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio 
Age 1.05(1.02 – 
1.09)*** 
1.02(0.99 – 
1.04)* 
1.03(1.00 – 
1.05)** 
1.04(1.01 – 1.07)*** 1.04(1.01 – 
1.07)*** 
1.04(1.00 – 
1.07)*** 
1.02(0.99 – 
1.04) 
1.05(1.02 – 
1.08)*** 
Sex(male) 0.76(0.18 – 
3.29) 
1.75(0.96 – 
3.19)* 
1.24(0.56 – 
2.76) 
1.38(0.58 – 3.39) 1.31(0.49 – 
3.48) 
0.61(0.14 – 
2.62) 
1.53(0.93 – 
3.17) 
0.93(0.28 – 
3.15) 
Higher 
education 
1.32(0.60 – 
2.90) 
3.00(1.94 – 
4.65)**** 
1.97(1.16 – 
3.36) 
1.49(0.81 – 2.74) 2.02(1.02 – 
4.00)** 
1.55(0.74 – 
3.23) 
2.81(1.62 – 
4.89)**** 
1.87(0.88 – 
3.96) 
Xhosa 1.80(0.75 – 
4.30) 
8.73(4.69 – 
16.23)**** 
6.59(2.97 – 
14.63)**** 
4.84(2.03 – 
11.54)**** 
8.84(2.70 – 
28.90)**** 
3.59(1.37 – 
9.41)*** 
4.26(2.20 – 
8.25)**** 
2.98(1.22 – 
7.29)** 
Current 
Residence 
3.09(1.40 – 
6.80)**** 
3.63(2.34 – 
5.65)**** 
3.80(2.26 – 
6.42)**** 
3.62(1.98 – 
6.61)**** 
3.13(1.64 – 
5.99)*** 
3.91(1.92 – 
7.98)**** 
2.33(1.37 – 
3.94)**** 
4.79(2.38 – 
9.65)**** 
Occupation         
Employed 1.32(0.61 – 
2.87) 
1.94(1.31 – 
2.87)*** 
1.75(1.07 – 
2.86)** 
1.00(0.55 – 1.85) 1.16(0.61 – 
2.21) 
0.83(0.29 – 
1.77) 
1.59(0.98 – 
2.57)* 
1.76(0.88 – 
3.50) 
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Job 
Duration 
1(0.99 – 
1.00) 
1(1.00 – 1.00) 1.00(0.98 – 
1.01) 
0.99(0.96 – 1.02) 1.00(0.99 – 
1.00) 
1.00(0.98 – 
1.02) 
1.00(1.00 – 
1.00) 
1.00(1.00 – 
1.00) 
Indoor 
exposure 
        
Brick house 3.63(1.67 – 
7.92)*** 
2.18(1.47 – 
3.24)**** 
2.34(1.43 – 
3.83)*** 
2.28(1.28 – 4.07)*** 1.57(0.84 – 
2.95) 
2.98(1.48 – 
6.00)*** 
1.66(1.02 – 
2.69)** 
3.58(1.78 – 
7.21)**** 
Shack 1.69(0.73 – 
3.95) 
1.75(1.12 – 
2.74)** 
1.77(1.02 – 
3.08)** 
1.64(0.85 – 3.14)* 2.05(1.05 – 
4.00)** 
1.29(0.57 – 
2.92) 
1.23(0.70 – 
2.18) 
0.84(0.34 – 
2.08) 
Other than 
brickhouse 
or shack 
1(-) 1(-) 1(-) 1(-) 1(-) 1(-) 1(-) 1(-) 
Air 
conditioning 
2.34(0.52 – 
10.63) 
11.00(3.92 – 
30.86)**** 
4.07(1.57 – 
10.57)*** 
3.83(1.33 – 11.00)** 2.29(0.65 – 
8.15) 
1.88(0.42 – 
8.47) 
5.80(2.32 – 
14.48)**** 
1.82(0.41 – 
8.18) 
Electricity 12.69(1.71 
– 94.06)*** 
21.45(7.80 – 
59.02)**** 
19.06(4.62 
– 
78.58)**** 
25.00(3.43 – 
182.26)*** 
21.09(2.88 – 
154.25)*** 
1(-) 21.02(5.10 – 
86.54)**** 
16.28(2.21 – 
119.76)*** 
Time Spent 
Cooking 
1.27(0.90 – 
1.81) 
1.00(0.80 – 
1.27) 
1.25(0.96 – 
1.63)* 
1.42(1.05 – 1.91)** 1.21(0.89 – 
1.65) 
1.42(1.03 – 
1.97)** 
0.91(0.67 – 
1.21) 
1.43(1.03 – 
1.98)** 
Electricity at 
5 years 
1.21(0.50 – 
2.92) 
1.30(0.84 – 
2.04) 
1.29(0.73 – 
2.26) 
1.57(0.83 – 2.96) 1.07(0.51 – 
2.22) 
2.07(0.99 – 
4.30)* 
1.44(0.85 – 
2.46) 
1.48(0.69 – 
3.17) 
Wood or 
coal at 5 
years 
3.26(1.51 – 
7.00)*** 
1.53(1.00 – 
2.34)** 
2.05(1.23 – 
3.42)*** 
1.75(0.95 – 3.21)* 1.30(0.66 – 
2.56) 
1.72(0.83 – 
3.56)* 
1.02(0.59 – 
1.75) 
1.64(0.79 – 
3.38) 
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Gas at 5 
years 
1.71(0.21 – 
13.64) 
2.11(0.68 – 
6.54) 
0.58(0.07 – 
4.53) 
1(-) 2.33(0.50 – 
10.87) 
1(-) 1.96(0.53 – 
7.29) 
1.34(0.17 – 
10.62) 
Paraffin at 5 
years 
0.76(0.18 – 
3.29) 
2.74(1.54 – 
4.88)*** 
1.69(0.81 – 
3.52) 
2.01(0.89 – 4.53)* 1.65(0.66 – 
4.10) 
0.61(0.14 – 
2.62) 
2.51(1.30 – 
4.87)*** 
2.72(1.13 – 
6.57)** 
Let air in 
most of time 
10.54(4.71 
– 23.58)*** 
3.58(2.04 – 
6.30)**** 
3.68(1.95 – 
6.92)**** 
3.49(1.70 – 7.15)*** 3.22(1.50 – 
6.94)*** 
4.66(2.10 – 
10.33)**** 
2.38(1.24 – 
4.60)** 
6.11(2.85 – 
13.04)**** 
Let air in 
some time 
0.98(0.44 – 
2.16) 
1.55(1.05 – 
2.29)** 
1.32(0.80 – 
2.16) 
1.05(0.58 – 1.90) 0.91(0.47 – 
1.73) 
0.96(0.46 – 
1.98) 
1.44(0.90 – 
2.33)* 
0.91(0.45 – 
1.88) 
Let air in 
rarely 
0.49(0.11 – 
2.10) 
3.39(2.07 – 
5.55)**** 
2.00(1.08 – 
3.69)** 
2.19(1.09 – 4.38)** 3.93(2.00 – 
7.72)**** 
2.12(0.92 – 
4.86)* 
4.53(2.62 – 
7.81)**** 
2.04(0.89 – 
4.66)* 
Use of 
extractor 
fan 
5.37(1.08 – 
26.54)** 
5.14(1.43 – 
18.47)** 
7.46(2.11 – 
26.44)*** 
4.79(1.20 – 19.10)** 5.68(1.41 – 
22.77)888 
4.31(0.88 – 
21.15)* 
2.82(0.71 – 
11.15)* 
7.39(1.83 – 
29.94)*** 
Carpets or 
rugs 
3.33(1.53 – 
7.25)*** 
1.75(1.11 – 
2.74)*** 
1.64(0.94 – 
2.86)* 
1.64(0.85 – 3.14)* 1.82(0.92 – 
3.60)* 
2.39(1.15 – 
4.99)** 
1.23(0.70 – 
2.18) 
2.28(1.10 – 
4.74)** 
Double 
glazing 
6.95(0.70 – 
69.04) 
1.10(0.11 – 
10.68) 
2.36(0.24 – 
23.00) 
1(-) 4.24(0.43 – 
41.64) 
5.63(0.57 – 
55.57)* 
1(-) 1(-) 
Age of 
Oldest 
Carpet(Mor
e than 5 
years) 
3.03(0.65 – 
14.05) 
1.52(0.52 – 
4.54) 
1.65(0.46- 
5.93) 
2.55(0.70 – 9.25) 1.82(0.40 – 
8.29) 
4.07(1.10 – 
15.04)** 
3.05(1.03 – 
9.02)** 
3.94(1.07 – 
14.52)** 
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Sleeping 
with open 
window 
0.55(0.25 – 
1.24)* 
0.50(0.33 – 
0.74)*** 
0.4(0.23 – 
0.69)*** 
1.60(0.93-2.72)* 1.52(0.85-2.70) 1.58(0.85-
2.93) 
2.99(1.93-
4.63)**** 
0.53(0.26 – 
1.10)* 
Sleep with 
open 
windows at 
night 
4.96(0.47 – 
36.82) 
3.36(0.67 – 
16.16.82)* 
1.41(0.16 – 
12.24) 
2.15(0.25 – 18.78) 6.50(1.16 – 
36.52)** 
3.36(0.38 – 
29.62) 
6.64(1.32 – 
33.47)** 
3.26(0.37 – 
28.68) 
Water 
damage to 
building or 
its content 
1.54(0.57 – 
4.18) 
4.91(2.97 – 
8.13)**** 
3.13(1.75 – 
5.62)**** 
3.35(1.73 – 
6.49)**** 
3.74(1.88 – 
7.44)** 
2.26(0.98 – 
5.21) 
4.22(2.42 – 
7.35)**** 
3.54(1.66 – 
7.58)*** 
Water 
damage in 
last 12 
months 
1.98(0.72 – 
5.41) 
4.44(2.58 – 
7.67)**** 
2.91(1.55 – 
5.48)*** 
2.71(1.31 – 5.61)*** 4.39(2.15 – 
8.94)**** 
2.43(1.09 – 
5.84)** 
3.85(2.11 – 
6.99)**** 
3.38(1.50 – 
7.59)*** 
Damp spots 
inside house 
in last 12 
months 
1.91(0.79 – 
4.64)* 
4.07(2.55 – 
6.51)**** 
3.25(1.87 – 
5.63)**** 
3.51(1.88 – 
6.57)**** 
3.23(1.65 – 
6.30)*** 
2.46(1.14 – 
5.34)** 
3.09(1.80 – 
5.21)**** 
3.17(1.52 – 
6.63)** 
Outdoor 
exposure 
        
Intervention 
to reduce 
allergen 
3.59(1.38 – 
9.35)*** 
3.41(1.85 – 
6.31)**** 
2.42(1.17 – 
5.00)** 
3.43(1.59 – 7.41)** 2.99(1.30 – 
6.89)** 
4.23(1.79 – 
9.97)*** 
3.20(1.62 – 
6.30)*** 
4.06(1.73 – 
9.55)*** 
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Pets 5.17(2.32 – 
11.52)**** 
3.88(3.34 – 
6.43)**** 
4.15(2.34 – 
7.34)**** 
5.84(3.12 – 
10.95)**** 
2.58(1.24 – 
5.35)** 
3.77(1.76 – 
8.11)*** 
3.37(1.91 – 
5.95)**** 
7.27(3.54 – 
14.92)**** 
Born in 
Village 
1(-) 0.48(0.18 – 
1.26)* 
0.59(0.18 – 
1.95) 
0.91(0.27 – 3.06) 1.08(0.32 – 
3.65) 
0.91(0.21 – 
3.95) 
0.53(0.16 – 
1.78) 
0.88(0.20 – 
3.82) 
Born in 
town 
1.71(0.77 – 
3.78) 
1.13(0.73 – 
1.73) 
1.51(0.90 – 
2.57)* 
1.41(0.76 – 2.63) 1.28(0.65 – 
2.51) 
1.46(0.70 – 
3.08) 
0.99(0.58 – 
1.71) 
0.60(0.24 – 
1.48) 
Born in 
suburb 
1(-) 1.68(0.56 – 
4.99) 
0.50(0.06 – 
3.82) 
0.76(0.10 – 5.87) 3.28(0.89 – 
12.09)* 
1.18(0.15 – 
9.26) 
2.41(0.75 – 
7.75)* 
1(-) 
Affected by 
animals, 
dust or 
pollen from 
trees or 
flowers 
4.78(0.96 – 
23.92)* 
8.36(2.00 – 
34.94)*** 
5.35(1.30 – 
22.04)** 
0.07(0.01 – 0.36)*** 7.19(0.82 – 
63.00)* 
8.94(2.13 – 
37.43)*** 
4.63(0.93 – 
23.15)* 
5.28(1.39 – 
20.09)** 
Exercise         
Walking 0.55(0.26 – 
1.18) 
0.88(0.60 – 
1.31) 
0.49(0.30 – 
0.80)*** 
0.56(0.31 – 1.00)** 1.23(0.64 – 
2.38) 
0.70(0.35 – 
1.42) 
1.38(0.83 – 
2.30) 
0.58(0.29 – 
1.15)* 
Active in 
past month 
1.07(0.36 – 
3.18) 
3.30(2.02 – 
3.40)**** 
2.16(1.18 – 
3.95)* 
1.89(0.93 – 3.86)* 3.86(1.97 – 
7.58)*** 
2.06(0.91 – 
4.78)* 
2.52(2.52 – 
4.47)*** 
3.77(1.79 – 
7.92)**** 
Frequency 
of physical 
activity 
1.00(0.83 – 
1.20) 
0.97(0.88 – 
1.07) 
0.97(0.84 – 
1.12) 
0.99(0.88 – 1.12) 0.97(0.84 – 
1.13) 
0.69(0.37 – 
1.30) 
0.96(0.82 – 
1.12) 
0.98(0.86 – 
1.13) 
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Physical 
activity 10 
years ago  
1.68(0.79 – 
3.60) 
4.27(2.86 – 
6.39)**** 
2.93(1.78 – 
4.83)**** 
4.06(2.19 – 
7.53)**** 
3.14(1.66 – 
5.94)**** 
4.29(2.00 – 
9.14)**** 
5.48(3.24 – 
9.25)**** 
4.49(2.11 – 
9.53)**** 
Psychosocial         
Receiving 
Emotional 
support 
1.72(0.80 – 
3.71) 
4.13(2.74 – 
6.24)**** 
4.01(2.34 – 
6.91)**** 
3.34(1.79 – 
6.25)**** 
5.49(2.59 – 
11.65)**** 
4.43(1.97 – 
9.96)**** 
3.71(2.21 – 
6.20)**** 
5.51(2.37 – 
12.84)**** 
Receiving 
emotional 
support 
within last 
12 months 
1.72(0.80 – 
3.71) 
4.13(2.74 – 
6.24)**** 
4.02(2.34 – 
6.91)**** 
3.34(1.79 – 
6.25)**** 
5.50(2.59 – 
11.65)**** 
4.43(1.97 – 
9.96)**** 
3.71(2.21 – 
6.20)**** 
5.51(2.37 – 
12.84) 
Receiving 
financial 
support 
1.54(0.72 – 
3.30) 
2.53(1.72 – 
3.73)**** 
2.53(1.72 – 
3.73)**** 
2.43(1.48 – 
3.98)**** 
2.49(1.39 – 
4.45)*** 
2.45(1.32 – 
4.57)*** 
2.63(1.30 – 
5.33)*** 
2.17(1.09 – 
4.30)** 
Tobacco Use         
Smoking 1.60(0.36 – 
7.10) 
4.16(1.93 – 
8.97)**** 
3.65(1.59 – 
8.41)** 
5.91(2.52 – 
13.87)**** 
2.94(1.06 – 
8.15)** 
2.07(0.59 – 
7.24) 
2.74(1.17 – 
6.46)** 
3.88(1.38 – 
10.93)** 
*denotes significance at p<0.15  
**denotes significance at p<0.05 
***denotes significance at p<0.01 
****denotes significance at p<0.001 
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 Bring up phlegm 
from chest at 
any time of day 
in the winter 
 
Woken up by 
heavy coughing 
at any time in 
the last 12 
months 
 
Attack of 
asthma in 
last 12 
months 
 
Medication 
for asthma 
control 
Self-
reported 
asthma 
Chest Pain Hypertension High Blood 
Cholesterol 
Variable Name Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds Ratio Odds ratio 
Age 1.00(0.96 – 1.03) 1.02(0.99 – 
1.04) 
0.98(0.93 – 
1.03) 
1.06(1.02 – 
1.11)*** 
1.04(1.01 – 
1.08)*** 
1.02(0.99 – 
1.05) 
1.08(1.05 – 
1.11)**** 
1.07(1.04 – 
1.11)**** 
Sex(male) 2.13(0.84 – 
5.36)* 
1.60(0.68 – 
3.74) 
1(-) 1(-) 0.96(0.29 – 
3.27) 
1.68(0.62 – 
4.50)* 
1.11(0.50 – 
2.45) 
2.10(077 – 
5.74)* 
Higher education 3.17(1.37 – 
7.37)*** 
3.40(1.68 – 
6.91)*** 
0.61(0.19 – 
2.00) 
0.60(0.18 – 
1.97) 
1.79(0.84 – 
3.81) 
1.95(0.92 – 
4.12)* 
1.63(0.99 – 
2.68) 
1.26(0.59 – 
2.70) 
Xhosa 3.09(1.26 – 
7.54)** 
2.38(1.20 – 
4.74)** 
0.76(0.23 – 
2.49) 
0.70(0.21 – 
2.31) 
2.35(1.00 – 
5.49)*** 
6.95(2.10 – 
22.90)*** 
5.54(2.71 – 
11.33)**** 
5.59(1.67 – 
18.64)*** 
Current 
Residence 
2.38(1.15 – 
4.91)** 
3.08(1.69 – 
5.61)**** 
0.74(0.20 – 
2.75) 
3.84(1.15 – 
12.81)** 
2.60(1.25 – 
5.41)** 
4.53(2.27 – 
9.05)**** 
3.70(2.22 – 
6.14)**** 
4.32(2.04 – 
9.15)**** 
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Occupation         
Employed 1.15(0.57 – 2.32) 1.14(0.63 – 
2.05) 
0.57(0.19 – 
1.72) 
0.75(0.20 – 
2.87) 
1.27(0.62 – 
2.58) 
1.48(0.74 – 
2.93) 
1.22(0.75 – 
1.98) 
1.18(0.55 – 
2.52) 
Job Duration 0.99(0.96 – 1.02) 1.00(1.00 – 
1.00) 
1.00(0.99 – 
1.00) 
0.96(0.87 – 
1.07) 
1.00(0.99 – 
1.00) 
0.98(0.94 – 
1.02) 
1.00(0.98 – 
1.01) 
0.98(0.95 – 
1.02) 
Indoor exposure         
Brick house 1.83(0.92 – 
3.61)* 
1.94(1.09 – 
3.43)** 
0.38(0.13 – 
1.15)* 
3.95(1.14 – 
13.66)** 
3.39(1.67 – 
6.87)*** 
2.32(1.18 – 
4.57)** 
2.76(1.71 – 
4.44)**** 
1.73(0.82 – 
3.64) 
Shack 1.40(0.64 – 3.07) 0.95(0.46 – 
1.96) 
0.54(0.16 – 
1.78) 
1.56(0.41 – 
5.97) 
2.07(0.98 – 
4.38)* 
1.90(0.91 – 
3.98)* 
1.54(0.89 – 
2.65)* 
2.53(1.17 – 
5.48)** 
Other than 
brickhouse or 
shack 
1(-) 1(-) 1(-) 1(-) 1(-) 1(-) 1(-) 1(-) 
Air conditioning 5.84(1.99 – 
17.11)*** 
1.85(0.52 – 
6.53) 
0.41(0.05 – 
3.28) 
1(-) 1.88(0.42 – 
8.47) 
2.89(0.81 – 
10.37) 
1.12(0.32 – 
3.92) 
2.17(0.48 – 
9.80) 
Electricity 16.80(2.29 – 
123.51)*** 
26.14(3.59 – 
190.47)*** 
0.18(0.02 – 
1.43)* 
4.50(0.57 – 
35.40) 
7.58(1.80 – 
31.47)*** 
16.80(2.29 – 
123.57)*** 
21.35(5.19 – 
87.89)**** 
13.70(1.85 – 
101.31)** 
Time Spent 
Cooking 
1.29(0.94 – 
1.79)* 
1.03(0.75 – 
1.42) 
0.91(0.51 – 
1.60) 
1.22(0.71 – 
2.08) 
1.24(0.88 – 
1.73) 
1.03(0.70 – 
1.50) 
0.99(0.75 – 
1.30) 
0.81(0.50 – 
1.31) 
Electricity at 5 
years 
1.42(0.67 – 3.02) 1.19(0.62 – 
2.30) 
1.54(0.34 – 
7.03) 
1.36(0.36 – 
5.20) 
1.54(0.72 – 
3.32) 
1.64(0.78 – 
3.43) 
0.65(0.35 – 
1.23) 
0.54(0.19 – 
1.58) 
Wood or coal at 5 
years 
1.37(0.65 – 2.85) 0.99(0.51 – 
1.90) 
0.20(0.06 – 
0.61)*** 
5.54(1.60 – 
19.19)*** 
2.41(1.44 – 
5.87)** 
1.01(0.47 – 
2.21) 
2.12(1.30 – 
3.48)*** 
1.56(0.71 – 
3.41) 
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Gas at 5 years 1.30(0.16 – 
10.29) 
1.89(0.41 – 
8.76) 
0.25(0.03 – 
2.11) 
1(-) 1.38(0.17 – 
10.47) 
1(-) 0.52(0.07 – 
4.07) 
1(-) 
Paraffin at 5 
years 
2.13(0.84 – 
5.36)* 
2.63(1.24 – 
5.58)** 
0.54(0.12 – 
2.51) 
1(-) 0.61(0.14 – 
2.62) 
4.49(2.04 – 
9.92)**** 
2.20(1.12 – 
4.32)** 
2.69(1.05 – 
6.90)** 
Let air in most of 
time 
2.51(1.04 – 
6.02)** 
2.89(1.39 – 
5.99)*** 
0.11(0.04 – 
0.34)**** 
12.79(3.77 – 
43.43)**** 
11.56(5.48 – 
24.37)**** 
3.04(1.31 – 
7.03)** 
3.23(1.73 – 
6.04)**** 
2.57(1.00 – 
6.58)* 
Let air in some 
time 
1.63(0.83 – 3.20) 1.79(1.02 – 
3.16)** 
3.18(0.70 – 
14.50)* 
1.48(0.45 – 
4.91) 
0.83(0.40 – 
1.75) 
1.13(0.57 – 
2.26) 
2.68(1.66 – 
4.31)**** 
1.58(0.76 – 
3.30) 
Let air in rarely 2.73(1.26 – 
5.90)** 
2.63(1.35 – 
5.10) 
0.84(0.18 – 
3.84) 
1(-) 0.86(0.30 – 
2.17) 
3.17(1.49 – 
6.73)*** 
1.16(0.60 – 
2.25) 
2.08(0.86 – 
5.02) 
Use of extractor 
fan 
4.04(0.83 – 
19.89) 
2.61(0.54 – 
12.63) 
0.19(0.02 – 
1.61)* 
6.38(0.74 – 
55.20)* 
7.65(1.89 – 
31.00)*** 
4.04(0.83 – 
19.78)* 
2.78(0.70 – 
10.98) 
2.13(0.26 – 
17.36) 
Carpets or rugs 2.50(1.22 – 
5.09)** 
0.95(0.46 – 
1.96) 
0.38(0.12 – 
1.18)* 
7.61(2.19 – 
26.45)** 
2.75(1.33 – 
5.67)*** 
2.84(1.41 – 
5.75)*** 
1.79(1.05 – 
3.05)** 
1.54(0.67 – 
3.54) 
Double glazing 5.29(0.54 – 
52.13) 
1(-) 1(-) 1(-) 5.63(0.57 – 
55.57)* 
5.28(0.54 – 
51.13) 
1(-) 1(-) 
Age of Oldest 
Carpet(More 
than 5 years) 
2.29(0.50 – 
10.47) 
2.44(0.67 – 
8.84) 
1(-) 3.79(0.46 – 
31.50) 
2.44(0.53 – 
11.19) 
5.69(1.74 – 
18.63)*** 
2.17(0.68 – 
6.90) 
1.26(0.16 – 
9.89) 
Sleeping with 
open window 
0.51(0.11 – 1.26) 0.71(0.39 – 
1.26) 
1.90(0.58 – 
6.24) 
0.68(0.20 – 
2.35) 
0.41(0.19 – 
0.90)** 
0.44(0.21 – 
0.93)* 
0.32(0.19 – 
0.55)**** 
0.23(0.09 – 
0.60)*** 
Sleep with open 
windows at night 
3.16(0.36 – 
27.79) 
2.06(0.24 – 
17.98) 
1(-) 11.56(1.24 – 
108.17)** 
3.63(0.38 – 
29.62) 
3.16(0.36 – 
27.79) 
1.27(0.15 – 
11.01) 
3.86(0.44 – 
34.08) 
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Water damage to 
building or its 
content 
2.09(0.92 – 
4.78)* 
4.84(2.59 – 
9.05)**** 
0.79(0.17 – 
3.64) 
2.66(0.69 – 
10.69) 
1.52(0.81 – 
2.55) 
4.52(2.18 – 
9.38)**** 
2.29(1.26 – 
4.13)**** 
2.70(1.15 – 
6.30)** 
Water damage in 
last 12 months 
1.83(0.73 – 4.59) 4.77(2.46 – 
9.23)**** 
0.62(0.13 – 
2.87) 
3.39(0.88 – 
13.15)* 
1.97(0.78 – 
4.96) 
4.47(2.08 – 
9.62)**** 
2.83(1.53 – 
5.25)*** 
3.51(1.49 – 
8.26)*** 
Damp spots 
inside house in 
last 12 months 
3.48(1.69 – 
7.15)*** 
4.42(2.41 – 
8.08)**** 
2.20(0.28 – 
17.13) 
3.26(0.93 – 
11.36)* 
1.47(0.62 – 
3.48) 
3.98(1.95 – 
8.05)**** 
2.22(1.27 – 
3.87)** 
4.09(1.90 – 
8.82)**** 
Outdoor 
exposure 
        
Intervention to 
reduce allergen 
3.91(1.67 – 
9.17)*** 
4.36(2.10 – 
9.07)**** 
0.27(0.07 – 
1.00)* 
2.72(0.57-
12.99) 
2.79(1.09 – 
7.12)** 
5.58(2.50 – 
12.46)**** 
3.53(1.81 – 
6.89)**** 
6.10(2.61 – 
14.27)**** 
Pets 4.00(1.91 – 
8.40)**** 
4.00(2.12 – 
7.59)**** 
0.31(0.09 – 
1.03)* 
9.09(2.70 – 
30.58)**** 
4.38(2.07 – 
9.29)**** 
2.97(1.37 – 
6.44)*** 
3.59(2.05 – 
6.31)**** 
2.26(0.93 – 
5.46)* 
Born in Village 1.36(0.40 – 4.65) 0.55(0.13 – 
2.35) 
1(-) 1(-) 1(-) 0.40(0.05 – 
3.02) 
0.96(0.36 – 
2.53) 
0.49(0.07 – 
3.70) 
Born in town 1.34(0.64 – 2.79) 0.76(0.38 – 
1.53) 
1.86(0.41 – 
8.50) 
2.54(0.76 – 
8.45)* 
1.68(0.81 – 
3.49) 
1.34(0.64 – 
2.79) 
1.13(0.67 – 
1.92) 
1.30(0.58 – 
2.90) 
Born in suburb 1.11(0.14 – 8.69) 1.59(0.35 – 
7.25) 
1(-) 1(-) 1(-) 2.47(0.53 – 
11.37) 
1.61(0.44 – 
5.82) 
1(-) 
Affected by 
animals, dust or 
pollen from trees 
or flowers 
28.00(7.08 – 
110.28)**** 
11.20(2.65 – 
47.40)*** 
6.86(1.69 – 
27.82)*** 
5.89(1.54 – 
22.44)*** 
5.59(1.36 – 
23.07)** 
6.63(1.60 – 
27.50)*** 
2.09(0.25 – 
17.22) 
5.36(1.41 – 
20.39)** 
Exercise         
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Walking 0.88(0.44 – 1.77) 1.22(0.67 – 
2.23) 
1.10(0.36 – 
3.42) 
0.47(0.14 – 
1.54) 
0.55(0.27 – 
1.10)* 
1.00(0.50 – 
2.02) 
0.85(0.53 – 
1.37) 
0.98(0.46 – 
2.10) 
Active in past 
month 
2.68(1.24 – 
5.80)** 
2.30(1.17 – 
4.52)** 
0.51(0.14 – 
1.89) 
1(-) 1.41(0.56 – 
3.51) 
3.12(1.55 – 
6.62)*** 
1.90(1.05 – 
3.44)** 
1.30(0.48 – 
3.51) 
Frequency of 
physical activity 
1.00(0.90 – 1.12) 0.85(0.67 – 
1.26) 
1.02(0.76 – 
1.37) 
- 0.99(0.83 – 
1.18) 
0.98(0.85 – 
1.14) 
1.06(0.96 – 
1.16) 
0.99(0.81 – 
1.20) 
Physical activity 
10 years ago  
3.55(1.74 – 
7.26)*** 
3.59(1.98 – 
6.51)**** 
0.37(0.12 – 
1.15)* 
2.93(0.85 – 
10.12)* 
1.69(0.85 – 
3.39)* 
3.12(1.55 – 
6.29)*** 
2.18(1.36 – 
3.50)*** 
5.89(2.48 – 
13.96)**** 
Psychosocial         
Receiving 
Emotional 
support 
4.09(1.89 – 
8.87)**** 
5.53(2.79 – 
10.97)**** 
0.93(0.31 – 
2.79) 
1.05(0.32 – 
3.48) 
1.86(0.92 – 
3.77)* 
3.52(1.67 – 
7.44)*** 
4.70(2.75 – 
8.02)**** 
3.10(1.40 – 
6.90)*** 
Receiving 
emotional 
support within 
last 12 months 
4.09(1.89 – 
8.87)**** 
5.53(2.79 – 
10.97)**** 
0.93(0.31 – 
2.79) 
1.05(0.32 – 
3.48) 
1.86(0.92 – 
3.76)* 
3.52(1.67 – 
7.44)*** 
4.70(2.75 – 
8.02)**** 
3.10(1.40 – 
6.90)*** 
Receiving 
financial support 
2.59(1.30 – 
5.13)*** 
2.47(1.39 – 
4.37)*** 
0.67(0.22 – 
2.00) 
1.46(0.44 – 
4.14) 
1.59(0.79 – 
3.18) 
1.80(0.92 – 
3.55)* 
2.48(1.54 – 
3.99)**** 
3.19(1.49 – 
6.84)*** 
Tobacco Use         
Smoking 7.69(3.11 – 
18.97)**** 
4.63(1.93 – 
11.11)*** 
0.58(0.07 – 
4.66) 
4.76(0.98 – 
23.16)* 
1.28(0.29 – 
5.65) 
2.78(0.91 – 
8.50)* 
3.87(1.72 – 
8.72)*** 
4.70(1.65 – 
13.40)*** 
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Appendix E: Single and two pollutant association between a 10µg/m3 increase in NO2 levels and cardiorespiratory outcomes  
 NO2 summer NO2 winter NO2 annual 
 Single pollutant Two pollutant Single pollutant Two Pollutant Single Pollutant Two Pollutant 
Doctor diagnosis of 
asthma 
1.02(0.53-1.79)1a 1.21(0.58-
2.51)1b 
0.84(0.44-1.72)1c 0.90(0.43-1.98)1d 1.01(0.41-2.09)1e 1.01(0.51-2.32)1f 
Asthma-symptom 
score ≥ 2* 
0.92(0.62-1.34)2a 1.11(0.69-
1.62)2b 
1.00(0.71-1.54)2c 1.11(0.73-1.61)2d 0.82(0.52-1.22)2e 1.00(0.60-1.51)2f 
Self-reported chest 
pain 
2.71(1.50-5.18)3a 2.49(1.17-
4.88)3b 
2.28(1.19-4.38)3c 2.32(1.24-4.49)3d 2.80(1.34-5.90)3e 2.92(1.33-6.14)3f 
Self-reported 
hypertension 
0.92(0.63-1.29)4a 0.81(0.38-
1.31)4b 
1.00(0.58-1.62)4c 1.00(0.62-1.61)4d 0.79(0.56-1.62)4e 0.93(0.52-1.62)4f 
Self-reported high 
cholesterol 
1.18(0.62-2.31)5a 1.31(0.61-
2.83)5b 
1.33(0.61-2.64)5c 1.39(0.72-2.81)5d 1.32(0.58-2.91)5e 1.61(0.73-3.63)5f 
Bold text denotes statistical significance at p < 0.05 
Appendix F displays list of confounders included in each model 
*Asthma symptom score calculated as sum of: Wheezing in the last 12 months, Shortness of breath in last 12 months, woken up by feeling of tight chest in the last 12 months, Attack of shortness of breath at rest in the 
last 12 months, Attack of shortness of breath after exercise in the last 12 months, Woken up by attack of shortness of breath in the last 12 months, Self-reported asthma, Medication for asthma control 
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Appendix F:  List of confounders included in the models investigating the association between NO2 levels and cardio respiratory 
outcomes 
 A b c d e f 
1 age, sex, smoke, 
damp spots inside 
house in last 12 
months, born in town, 
affected by animals 
dust or pollen from 
trees or flowers 
age, sex, smoke age, sex, smoke, 
brick house, damp 
spots inside house in 
last 12 months, 
intervention to reduce 
allergen, affected by 
animals dust or pollen 
from trees or flowers 
age, sex, smoke, 
damp spots inside 
house in last 12 
months, born in town, 
affected by animals 
dust or pollen from 
trees or flowers 
Age, sex, smoke, 
born in town, affected 
by animals dust or 
pollen from trees or 
flowers 
age, sex, smoke, 
affected by animals 
dust or pollen from 
trees or flowers 
2 age, sex, smoke, 
current residence, 
brick house 
age, sex, smoke, 
affected by animals 
dust or pollen from 
trees or flowers 
age, sex, smoke, 
brick house, 
electricity 
age, sex, smoke, 
brick house 
age, sex, smoke, 
brick house, damp 
spots inside house in 
last 12 months 
age, sex smoke, brick 
house 
3 age, sex, smoke, 
current residence, 
active in past month, 
receiving financial 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
brick house, active in 
past month, receiving 
financial support 
Age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
active in past month, 
receiving financial 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
4 age, sex, smoke, 
current residence, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
receiving, receiving 
emotional support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
5 age, sex, smoke, 
receiving emotional 
support, receiving, 
financial support 
age, sex, smoke, 
active in past month, 
receiving financial 
support 
age, sex, smoke, 
receiving financial 
support 
age, sex, smoke, 
receiving, receiving 
emotional support, 
receiving financial 
support 
age, sex, smoke, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke 
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 Appendix G: Single- and two-pollutant association between a 10µg/m3 increase in PM2.5 levels and cardiorespiratory outcomes 
 
Bold text denotes statistical significance at p < 0.05 
Appendix H displays list of confounders included in each model 
*Asthma symptom score calculated as sum of: Wheezing in the last 12 months, Shortness of breath in last 12 months, woken up by feeling of tight chest in the last 12 months, Attack of shortness of breath at rest in the 
last 12 months, Attack of shortness of breath after exercise in the last 12 months, Woken up by attack of shortness of breath in the last 12 months, Self-reported asthma, Medication for asthma control 
 PM2.5 summer PM2.5 winter PM2.5 annual 
 Single-pollutant Two-pollutant Single-pollutant Two-Pollutant Single-Pollutant Two-Pollutant 
Doctor diagnosis of 
asthma 
0.53(0.11-2.34)1a 0.28(0.01-2.41)1b 0.76(0.31-
2.04)1c 
0.83(0.33-1.92)1d 0.79(0.21-
3.04)1e 
0.64(0.10-2.69)1f 
Asthma-symptom score 
≥ 2* 
0.48(0.22-1.13)2a 0.28(0.12-1.01)2b 0.69(0.44-
1.09)2c 
0.58(0.41-1.03)2d 0.52(0.22-
0.91)2e 
0.39(0.21-0.93)2f 
Self-reported chest pain 3.04(0.73-
12.27)3a 
0.87(0.16-5.14)3b 0.76(0.43-
1.76)3c 
0.74(0.34-1.49)3d 0.88(0.31-
3.17)3e 
0.48(0.11-2.13)3f 
Self-reported 
hypertension 
1.00(0.44-2.83)4a 1.49(0.44-5.71)4b 1.12(0.63-
1.88)4c 
1.08(0.63-2.01)4d 1.03(0.37-
2.40)4e 
1.00(0.8-2.71)4f 
Self-reported high 
cholesterol 
1.24(0.29-5.61)5a 0.80(0.11-5.76)5b 0.68(0.32-
1.47)5c 
0.64(0.32-1.42)5d 0.49(0.11-
2.01)5e 
0.42(0.11-1.72)5f 
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 Appendix H:  List of confounders included in the models investigating the association between PM2.5 levels and cardiorespiratory 
outcomes 
 A b c d e f 
1 age, sex, smoke, pet, 
affected by animals 
dust or pollen from 
trees or flowers 
age, sex, smoke,  
affected by animals 
dust or pollen from 
trees or flowers 
age, sex, smoke, pet, 
affected by animals 
dust or pollen from 
trees or flowers 
age, sex, smoke, born 
in town,  affected by 
animals dust or pollen 
from trees or flowers 
age, sex, smoke age, sex, smoke, born 
in town, affected by 
animals dust or pollen 
from trees or flowers 
2 age, sex, smoke, 
brick house 
age, sex, smoke, 
brick house,  damp 
spots inside house in 
last 12 months 
age, sex, smoke, 
brick house 
age, sex ,smoke, 
damp spots inside 
house in last 12 
months 
age, sex, smoke Age, sex, smoke, 
employed,  damp 
spots inside house in 
last 12 months 
3 age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
4 age, sex, smoke, 
receiving emotional 
support 
Age, sex, smoke, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
active in past month, 
receiving emotional 
support 
age, sex, smoke, 
receiving emotional 
support 
5 age, sex, smoke, 
receiving financial 
support 
Age, sex, smoke, 
receiving financial 
support 
age, sex, smoke age, sex, smoke, 
active in past month, 
receiving emotional 
support, receiving 
financial support 
age, sex, smoke age, sex, smoke, 
receiving financial 
support 
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To access and submit an article already in production, please see the guidelines here. 
  
Author Guidelines 
  
Please view the Author Tutorial for guidance on how to submit on Editorial Manager.  
  
Please take the time to familiarise yourself with the policies and processes below. If you still 
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• Submission and peer-review 
• Production process 
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SAMJ Policies 
Type of articles considered by the SAMJ 
The SAMJ will no longer limit the articles accepted to those that have ‘general medical 
content’, but is intending to capture the spectrum of medical and health sciences, grouped by 
relevance to the country’s burdens of disease. This content will include research in the 
social sciences and economics that is relevant to the medical issues around our burden of 
disease. Please see ‘A new vision for the SAMJ – and a call for papers’ for a full discussion 
of the new directions for the SAMJ. 
We accept the following types of articles: 
• Research 
• Reviews 
• Clinical trials 
• Editorials 
• In Practice (Previously Forum incl. Case 
Reports) 
• Correspondence 
• Obituaries 
• Book reviews 
• Ad hoc supplements e.g. guidelines, 
conference/congress abstracts, Festschrifts* 
  
  
The following articles are by invitation only: 
• Guest editorial 
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• Continuing Medical Education (CME) 
  
*Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
  
Publication Fees  
All articles published in the South African Medical Journal are open access and freely 
available online upon publication. This is made possible by applying a business model to 
offset the costs of peer review management, copyediting, design and 
production, by charging a publication fee of R5 250 (ex vat) for each research article 
published. The charge applies only to Research articles submitted after 1 March 2017. The 
publication fee is standard and does not vary based on length, colour, figures, or other 
elements. 
 
When submitting a Research article to the SAMJ, the submitting author must agree to pay 
the publication fee should the article be accepted for publication. The publicaiton fee is 
payable when your manuscript is editorially accepted and before production commences for 
publication. The submitting author will be notified that payment is due and given details on 
the available methods of payment. Prompt payment is advised; the article will not enter into 
production until payment is received. 
Queries can be directed to claudian@hmpg.co.za. 
 
Please refer to the section on ‘Sponsored Supplements’ regarding the publication of 
supplements, where a charge is applicable. Queries can be directed to dianes@hmpg.co.za 
or claudian@hmpg.co.za 
Authorship 
Named authors must consent to publication. Authorship should be based on: (i) substantial 
contribution to conceptualisation, design, analysis and interpretation of data; (ii) drafting or 
critical revision of important scientific content; or (iii) approval of the version to be 
published. These conditions must all be met (uniform requirements for manuscripts 
submitted to biomedical journals; refer to www.icmje.org) 
  
If authors’ names are added or deleted after submission of an article, or the order of the 
names is changed, all authors must agree to this in writing. 
  
Please note that co-authors will be requested to verify their contribution upon submission. 
Non-verification may lead to delays in the processing of submissions. 
Author contributions should be listed/described in the manuscript. 
  
Conflicts of interest 
Conflicts of interest can derive from any kind of relationship or association that may 
influence authors’ or reviewers’ opinions about the subject matter of a paper. The existence 
of a conflict – whether actual, perceived or potential – does not preclude publication of an 
article. However, we aim to ensure that, in such cases, readers have all the information they 
need to enable them to make an informed assessment about a publication’s message and 
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conclusions. We require that both authors and reviewers declare all sources of support for 
their research, any personal or financial relationships (including honoraria, speaking fees, 
gifts received, etc) with relevant individuals or organisations connected to the topic of the 
paper, and any association with a product or subject that may constitute a real, perceived or 
potential conflict of interest. If you are unsure whether a specific relationship constitutes a 
conflict, please contact the editorial team for advice. If a conflict remains undisclosed and is 
later brought to the attention of the editorial team, it will be considered a serious issue 
prompting an investigation with the possibility of retraction. 
  
Research ethics committee approval 
Authors must provide evidence of Research Ethics Committee approval of the research 
where relevant. Ensure the correct, full ethics committee name and reference number is 
included in the manuscript. 
If the study was carried out using data from provincial healthcare facilities, or required 
active data collection through facility visits or staff interviews, approval should be sought 
from the relevant provincial authorities. For South African authors, please refer to the 
guidelines for submission to the National Health Research Database. Research involving 
human subjects must be conducted according to the principles outlined in the Declaration of 
Helsinki. Please refer to the National Department of Health’s guideline on Ethics in Health 
research: principles, processes and structuresto ensure that the appropriate requirements for 
conducting research have been met, and that the HPCSA’s General Ethical Guidelines for 
Health Researchers have been adhered to. 
  
Clinical trials 
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should 
be registered with the appropriate national clinical trial registry (or any international primary 
register, if relevant), and the trial registration number should be cited at the end of the 
abstract. All clinical trial reports must also contain a data sharing statement as per the 
recommendations of the ICMJE. Statements are to indicate: 
• whether individual deidentified participant data will be shared; 
• what data in particular will be shared; whether additional, related documents will be 
available; 
• when the data will become available and for how long; by what access criteria data will be 
shared. 
  
Please see the ICJME announcement for further details and illustrative examples of data 
sharing statements: ICMJE Data Sharing Statements for Clinical Trials 
  
Since 1st December 2005, all clinical trials conducted in South Africa have been required to 
be registered in the South African National Clinical Trials Register. The SAMJ therefore 
requires that clinical trials be registered in the relevant public trials registry at or before the 
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time of first patient enrollment as a condition for publication. The trial registry name and 
registration number must be included in the manuscript. 
  
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
  
  
Patient Consent 
Information that would enable identification of individual patients should not be published 
in written descriptions, photographs, and pedigrees unless the information is essential for 
scientific purposes and the patient (or parent or guardian) has given informed written 
consent for publication and distribution. We further recommend that the published article is 
disseminated not only to the involved researchers but also to the patients/participants from 
whom the data was drawn. Refer to Protection of Research Participants. The signed consent 
form should be submitted with the manuscript to enable verification by the editorial team. 
  
Other individuals 
Any individual who is identifiable in an image must provide written agreement that the 
image may be used in that context in the SAMJ. 
  
Copyright notice 
Copyright remains in the Author’s name. The work is licensed under a Creative Commons 
Attribution - Noncommercial Works License. Authors are required to complete and sign 
an Author Agreement form that outlines Author and Publisher rights and terms of 
publication. The Author Agreement form should be uploaded along with other 
submissions files and any submission will be considered incomplete without it. 
  
Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
main findings of your paper have been presented at a conference and published in abstract 
form, to avoid copyright infringement. All research already published as ‘Conference 
proceedings’ needs to be substantially re-written, with a new title, a new abstract and new 
and important results to back up any study before it will be considered for a new 
publication. The SAMJ does not hold itself responsible for statements made by the authors. 
Previously published images 
If an image/figure has been previously published, permission to reproduce or alter it must be 
obtained by the authors from the original publisher and the figure legend must give full 
credit to the original source. This credit should be accompanied by a letter indicating that 
permission to reproduce the image has been granted to the author/s. This letter should be 
uploaded as a supplementary file during submission. 
  
  
Privacy statement 
125 
 
The SAMJ is committed to protecting the privacy of its website and submission system 
users. The names, personal particulars and email addresses entered in the website or 
submission system will not be made available to third parties without the user’s permission 
or due process. By registering to use the website or submission system, users consent to 
receive communication from the SAMJ or its publisher HMPG on matters relating to the 
journal or associated publications. Queries with regard to privacy may be directed to 
publishing@hmpg.co.za. 
  
Ethnic/race classification 
Use of racial or ethnicity classifications in research is fraught with problems. If you choose 
to use a research design that involves classification of participants based on race or 
ethnicity, or discuss issues with reference to such classifications, please ensure that you 
include a detailed rationale for doing so, ensure that the categories you describe are 
carefully defined, and that socioeconomic, cultural and lifestyle variables that may underlie 
perceived racial disparities are appropriately controlled for. Please also clearly specify 
whether race or ethnicity is classified as reported by the patient (self-identifying) or as 
perceived by the investigators. Please note that is not appropriate to use self-reported or 
investigator-assigned racial or ethnic categories for genetic studies. 
  
Continuing Professional Development (CPD) 
SAMJ is an HPCSA-accredited service provider of CPD materials. Principal authors can 
earn up to 15 CPD continuing education units (CEUs) for publishing an article; co-authors 
are eligible to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. Each 
month, SAMJ also publishes a CPD-accredited questionnaire relating to the academic 
content of the journal. Successful completion of the questionnaire with a pass rate of 70% 
will earn the reader 3 CEUs. Administration of our CPD programme is managed by Medical 
Practice Consulting. To complete questionnaires and obtain certificates, please visit MRP 
Consulting 
  
Manuscript preparation 
Preparing an article for anonymous review 
  
To ensure a fair and unbiased review process, all submissions are to include an anonymised 
version of the manuscript. The exceptions to this are Correspondence, Book reviews and 
Obituary submissions. 
  
Submitting a manuscript that needs additional blinding can slow down your review process, 
so please be sure to follow these simple guidelines as much as possible: 
• An anonymous version should not contain any author, affiliation or particular institutional 
details that will enable identification. 
• Please remove title page, acknowledgements, contact details, funding grants to a named 
person, and any running headers of author names. 
• Mask self-citations by referring to your own work in third person. 
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General article format/layout 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-point 
Times New Roman font, and contain no unnecessary formatting (such as text in boxes). 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) and 
contact details of ALL authors must be provided in the manuscript and in the online 
submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
• Include sections on Acknowledgements, Conflict of Interest, Author Contributions and 
Funding sources. If none is applicable, please state ‘none’.  
• Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but '50%' 
and '19ºC'. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B for 
beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the text. You may use the table 
format –this is the only exception. Please DO NOT use fill, format lines and so on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, although 
they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ can 
be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
• Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
• HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
• OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
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• Bennet et al. Standardized human pedigree nomenclature: Update and assessment of the 
recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 
Preparation notes by article type 
• Research 
• Editorials 
• CME 
• In Practice and Case reports 
• Reviews 
• Clinical trials 
• Correspondence 
• Obituaries 
• Book reviews 
• Guidelines 
  
Research 
Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that 
clearly lay out the rationale for conducting the study. Some common reasons for conducting 
a study are: to fill a gap in the literature, a logical extension of previous work, or to answer 
an important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need 
to. Results should describe the study sample as well as the findings from the study itself, but 
all interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The 
conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
  
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the intervention, 
primary and secondary outcomes, any specific analyses that were done on the data. 
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o Results: first sentence must be brief population and sample description; outline the results 
according to the methods described. Primary outcomes must be described first, even if they 
are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
• Do not include any references in the abstracts. 
  
  
Here is an example of a good abstract. 
  
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational attainment, co-existing disease 
indicators, etc)that may have an impact on the study results. Clearly define how participants 
were enrolled, and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key characteristics of 
comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, 
the exact level of statistical significance and the number need to treat/harm. Whenever 
possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is to present 
this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean 
(SD). 
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• Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 
not go beyond the data in the article. 
  
Editorials 
Guideline word limit: 1 000 words 
  
These opinion or comment articles are usually commissioned but we are happy to consider 
and peer review unsolicited editorials. Editorials should be accessible and interesting to 
readers without specialist knowledge of the subject under discussion and should have an 
element of topicality (why is a comment on this issue relevant now?) There should be a 
clear message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
• expert opinion 
• personal clinical experience 
• observational studies 
• trials 
• systematic reviews. 
  
CME (by invite only) 
CME is intended to provide readers with practical, up-to-date information on medical and 
related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to adhere 
strictly to the guidelines on word count as we have a page limit for the print issue of 
the SAMJ. We reserve the right to place some tables and reference lists online if this is 
necessary for space. 
In practice, this means that each CME topic usually covers two issues of the print issue of 
the SAMJ. 
130 
 
  
The guest editor, in consultation with the editor, is responsible for convening a team of 
authors, deciding on the subjects to be covered and for reviewing the manuscripts submitted. 
The suggestion is for 4 - 5 articles, although there is some room for flexibility contingent on 
discussions with the editor. 
  
For queries about these guidelines please feel free to contact the CME editor, Dr Bridget 
Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)21 789 2331). 
  
Review process 
The guest editor reviews the articles and returns them to the CME editor for review and final 
approval. 
  
Guest editorials 
Guideline word limit: 1 000 words 
• Include the guest editor’s personal details (qualifications, positions, affiliation, e-mail 
address, and a short personal profile (50words)). 
• If possible, include a photograph of the author(s) at high enough resolution for print. It is 
preferable to provide two guest editorials, one for each issue, so that the content of the 
articles in each issue is covered. 
  
Articles 
Guideline word limit: 2 000 - 3 000 words 
• Each article requires an abstract of ±200 words. 
• The editor reserves the right to shorten articles but will send a substantially shortened article 
back for author approval. 
  
Personal details 
Please supply: Your qualifications, position and affiliations and MP number (used for CPD 
points); Address, telephone number and fax number, and your e-mail address; and a short 
personal profile (50words)and a few words about your current fields of interest. 
  
In Practice 
Guideline word limit: 2 000 - 3 000words 
  
This section includes articles that would previously have been accepted into the Forum 
section, and case reports. 
In practice articles are those that draw attention to specific issues of clinical, economic or 
political interest regarding medicine and healthcare in southern Africa. They are assigned to 
a topic: 
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• Case report 
• Clinical practice 
• Clinical alert 
• Issues in medicine 
• Issues in public health 
• Healthcare delivery 
• Consensus/Position statement 
• Medicine and the environment 
• Medicine and the law 
• Cochrane corner 
  
  
An In Practice article should follow the following format – sub-headings are not necessary, 
but may be used for clarity: 
• Author affiliations and qualifications: to be the same as for Research. Provide all authors’ 
names and initials, qualifications and full affiliations, and corresponding author. 
• Short abstract: does not need to be structured, but should capture the essential features of the 
article 
• Introduction: the reason for the article and the issue being addressed 
• Recent research, discussion, local policy around the issue – include your own research where 
appropriate 
• All statements should be referenced and, if opinion only, this should be stated 
• Discussion: how this article adds to the discussion around a particular topic 
• If a clinical practice or policy point is at issue, this needs to be emphasised, using a box with 
highlights if appropriate. 
  
Essentially In practice is an opportunity for a more discursive approach to topics of clinical, 
economic or political importance in southern African health systems. It is not an opportunity 
to put forward unsubstantiated opinions! 
  
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from Africa, 
preferably southern Africa unless the condition is common to all African countries, and 
must be either a completely new description of a clinical condition or result (use Google!) or 
a case that highlights important practice or management issues. 
  
Please use the following format for case reports: 
• Title of case: do not include the words ‘a case report’ in the title 
• Summary/abstract:  up to 150 words summarising the case presentation and outcome 
• Background: why is this case important and why did you write it up? 
• Case presentation: presenting features, medical, social, family history as appropriate 
• Case management: should be according to best practice, and if not, please explain why 
• Investigations, if relevant: save space by simply saying ‘normal’ if, for example, renal 
function was completely normal, rather than listing normal results, highlight the abnormal – 
or indeed the normal if this is clinically significant 
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• Differential diagnosis, if relevant 
• Treatment, if relevant 
• Outcome and follow-up 
• Discussion – a VERY BRIEF review of similar published cases 
• Teaching points: 3 - 5 bullet points 
• References: as per the SAMJ house style 
• Tables and figures: keep to a minimum. Use clinical images where relevant – we need hi-res 
versions for print, and identifiable persons must have a consent form 
• Patient consent: please include a statement about patient consent to a written case report. This 
should be uploaded as a supplementary file. 
  
 
